<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Remicade II-141-G II-142 PI EN clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-name:"Heading 1\,D70AR\,Info rubrik 1\,titel 1";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{mso-style-name:"Heading 2\,D70AR2";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-name:"Heading 3\,D70AR3\,titel 3\,OLD Heading 3";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-name:"Heading 4\,D70AR4\,titel 4";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:center;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-name:"Heading 5\,D70AR5\,titel 5";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char1 Char\,Comment Text Char Char Char\,Comment Text Char1\,Char";
	mso-style-link:"Comment Text Char\,Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Char Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	layout-grid-mode:line;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:-.1pt;
	margin-bottom:0in;
	margin-left:14.2pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
address
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.dunjalist, li.dunjalist, div.dunjalist
	{mso-style-name:dunjalist;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Comic Sans MS";
	font-weight:bold;}
p.plaintext, li.plaintext, div.plaintext
	{mso-style-name:"plain text";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.western, li.western, div.western
	{mso-style-name:western;
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.SubheadingBold, li.SubheadingBold, div.SubheadingBold
	{mso-style-name:"Subheading Bold";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Ballongtext, li.Ballongtext, div.Ballongtext
	{mso-style-name:Ballongtext;
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.Inforubrik2, li.Inforubrik2, div.Inforubrik2
	{mso-style-name:"Info rubrik 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-before:always;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Annexheading2, li.Annexheading2, div.Annexheading2
	{mso-style-name:"Annex heading2";
	margin:0in;
	text-align:center;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.SynopsisChar
	{mso-style-name:"Synopsis Char";
	font-weight:bold;}
p.Kommentarsmne, li.Kommentarsmne, div.Kommentarsmne
	{mso-style-name:Kommentars\00E4mne;
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Char Char";
	mso-style-link:"Comment Text\,Comment Text Char1 Char\,Comment Text Char Char Char\,Comment Text Char1\,Char";
	color:black;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>SUMMARY
OF PRODUCT CHARACTERISTICS</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade 100&nbsp;mg powder for concentrate
for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 100&nbsp;mg of
infliximab. Infliximab is a chimeric human&#8209;murine IgG1&nbsp;monoclonal
antibody produced in murine hybridoma cells by recombinant DNA technology.
After reconstitution each ml contains 10&nbsp;mg of infliximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Powder for concentrate for solution for
infusion (</span><span lang=EN-GB>powder for concentrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The powder is a freeze&#8209;dried white
pellet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Rheumatoid
arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade, in combination with methotrexate,
is indicated for the reduction of signs and symptoms as well as the improvement
in physical function in:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>adult patients with active disease when the
response to disease&#8209;modifying antirheumatic drugs (DMARDs), including
methotrexate, has been inadequate.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>adult patients with severe, active and
progressive disease not previously treated with methotrexate or other DMARDs.</span></p>

<p class=MsoNormal><span lang=EN-GB>In these patient populations, a reduction
in the rate of the progression of joint damage, as measured by X&#8209;ray, has
been demonstrated (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
Crohn&#8217;s disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is indicated for:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treatment of moderately to severely active
Crohn&#8217;s disease, in adult patients who have not responded despite a full
and adequate course of therapy with a corticosteroid and/or an
immunosuppressant; or who are intolerant to or have medical contraindications
for such therapies.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>treatment of fistulising, active Crohn&#8217;s
disease, in adult patients who have not responded despite a full and adequate
course of therapy with conventional treatment (including antibiotics, drainage
and immunosuppressive therapy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
Crohn&#8217;s disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is indicated for treatment of
severe, active Crohn&#8217;s disease, in children and adolescents aged 6 to 17&nbsp;years,
who have not responded to conventional therapy including a corticosteroid, an
immunomodulator and primary nutrition therapy; or who are intolerant to or have
contraindications for such therapies. Remicade has been studied only in
combination with conventional immunosuppressive therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Ulcerative
colitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is indicated for treatment of
moderately to severely active ulcerative colitis in adult patients who have had
an inadequate response to conventional therapy including corticosteroids and 6&#8209;mercaptopurine
(6&#8209;MP) or azathioprine (AZA), or who are intolerant to or have medical
contraindications for such therapies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
ulcerative colitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is indicated for treatment of
severely active ulcerative colitis, in children and adolescents aged 6 to 17&nbsp;years,
who have had an inadequate response to conventional therapy including
corticosteroids</span><span lang=EN-GB> and 6&#8209;MP or AZA, or who are
intolerant to or have medical contraindications for such therapies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='layout-grid-mode:line'>Ankylosing spondylitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Remicade is
indicated for treatment of severe, active ankylosing spondylitis, in adult
patients who have responded inadequately to conventional therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK1"><u><span
lang=EN-GB style='layout-grid-mode:line'>Psoriatic arthritis</span></u></a></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Remicade is
indicated for treatment of active and progressive psoriatic arthritis in adult
patients when the response to previous DMARD therapy has been inadequate.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Remicade should
be administered</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in combination with methotrexate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>or alone in patients who show intolerance to
methotrexate or for whom methotrexate is contraindicated</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade has been shown to improve physical
function in patients with psoriatic arthritis, and to reduce the rate of
progression of peripheral joint damage as measured by X&#8209;ray in patients
with polyarticular symmetrical subtypes of the disease (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Psoriasis</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Remicade is
indicated for treatment of moderate to severe plaque psoriasis in adult
patients who failed to respond to, or who have a contraindication to, or are
intolerant to other systemic therapy including ciclosporin, methotrexate or
PUVA (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade treatment is to be initiated and
supervised by qualified physicians experienced in the diagnosis and treatment
of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis,
psoriatic arthritis or psoriasis. </span><span lang=EN-GB>Remicade should be
administered intravenously. </span><span lang=EN-GB>Remicade infusions should
be&nbsp;administered by qualified healthcare professionals trained </span><span
lang=EN-GB>to detect any infusion&#8209;related issues.</span><span lang=EN-GB>
Patients treated with Remicade should be given the package leaflet and the patient
reminder card.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During Remicade treatment, other concomitant
therapies, e.g., corticosteroids and immunosuppressants should be optimised.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Posology</span></u></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults (&#8805;&nbsp;18&nbsp;years)</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Rheumatoid
arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;mg/kg given as an intravenous
infusion followed by additional 3&nbsp;mg/kg infusion doses at 2 and
6&nbsp;weeks after the first infusion, then every 8&nbsp;weeks thereafter.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade must be given concomitantly with
methotrexate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data suggest that the clinical
response is usually achieved within 12&nbsp;weeks of treatment. </span><span
lang=EN-GB>If a patient has an inadequate response or loses response after this
period, consideration may be given to increase the dose step&#8209;wise by </span><span
lang=EN-GB>approximately 1.5&nbsp;mg/kg, </span><span lang=EN-GB>up to a
maximum of 7.5&nbsp;mg/kg every 8&nbsp;weeks. Alternatively, administration of
3&nbsp;mg/kg as often as every 4&nbsp;weeks may be considered. If adequate
response is achieved, patients should be continued on the selected dose or dose
frequency. </span><span lang=EN-GB>Continued therapy should be carefully
reconsidered in patients who show no evidence of therapeutic benefit within the
first 12&nbsp;weeks of treatment or after dose adjustment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Moderately to severely active
Crohn&#8217;s disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous
infusion followed by an additional 5&nbsp;mg/kg infusion 2&nbsp;weeks after the
first infusion. If a patient does not respond after 2&nbsp;doses, no additional
treatment with infliximab should be given. Available data do not support
further infliximab treatment, in patients not responding within 6&nbsp;weeks of
the initial infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In responding patients, the alternative
strategies for continued treatment are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Maintenance: Additional infusion of 5&nbsp;mg/kg
at 6&nbsp;weeks after the initial dose, followed by infusions every 8&nbsp;weeks
or</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Re&#8209;administration: Infusion of 5&nbsp;mg/kg
if signs and symptoms of the disease recur (see &#8216;Re&#8209;administration&#8217;
below and section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although comparative data are lacking, l</span><span
lang=EN-GB>imited data in patients who initially responded to 5&nbsp;mg/kg but
who lost response indicate that some patients may regain response with dose
escalation (see section&nbsp;5.1). Continued therapy should be carefully
reconsidered in patients who show no evidence of therapeutic benefit after dose
adjustment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fistulising, active Crohn&#8217;s
disease</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous
infusion followed by additional 5&nbsp;mg/kg infusions at 2 and 6&nbsp;weeks
after the first infusion. If a patient does not respond after 3&nbsp;doses, no
additional treatment with infliximab should be given.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In responding patients, the alternative
strategies for continued treatment are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Maintenance: Additional infusions of 5&nbsp;mg/kg
every 8&nbsp;weeks or</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Re&#8209;administration: Infusion of 5&nbsp;mg/kg
if signs and symptoms of the disease recur followed by infusions of 5&nbsp;mg/kg
every 8&nbsp;weeks (see &#8216;Re&#8209;administration&#8217; below and section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Although
comparative data are lacking, l</span><span lang=EN-GB>imited data in patients
who initially responded to 5&nbsp;mg/kg but who lost response indicate that
some patients may regain response with dose escalation (see section&nbsp;5.1).
Continued therapy should be carefully reconsidered in patients who show no
evidence of therapeutic benefit after dose adjustment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In Crohn&#8217;s disease, experience with
re</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>administration if signs
and symptoms of disease recur is limited and comparative data on the
benefit/risk of the alternative strategies for continued treatment are lacking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Ulcerative
colitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous
infusion followed by additional 5&nbsp;mg/kg infusion doses at 2 and 6&nbsp;weeks
after the first infusion, then every 8&nbsp;weeks thereafter.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data suggest that the clinical
response is usually achieved within 14&nbsp;weeks of treatment, i.e. three
doses. Continued therapy should be carefully reconsidered in patients who show
no evidence of therapeutic benefit within this time period.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Ankylosing
spondylitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous
infusion followed by additional 5&nbsp;mg/kg infusion doses at 2 and 6&nbsp;weeks
after the first infusion, then every 6 to 8&nbsp;weeks. If a patient does not
respond by 6&nbsp;weeks (i.e. after 2&nbsp;doses), no additional treatment with
infliximab should be given.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Psoriatic
arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>5&nbsp;mg/kg
given as an intravenous infusion followed by additional 5&nbsp;mg/kg infusion
doses at 2 and 6&nbsp;weeks after the first infusion, then every 8&nbsp;weeks
thereafter.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Psoriasis</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>5&nbsp;mg/kg
given as an intravenous infusion followed by additional 5&nbsp;mg/kg infusion
doses at 2 and 6&nbsp;weeks after the first infusion, then every 8&nbsp;weeks
thereafter.</span><span lang=EN-GB> If a patient shows no response after
14&nbsp;weeks (i.e. after 4&nbsp;doses), no additional treatment with
infliximab should be given.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Re</span></u><u><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>administration for Crohn&#8217;s disease and rheumatoid arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If the signs and symptoms of disease recur,
Remicade can be re&#8209;administered within 16&nbsp;weeks following the last infusion.
In clinical studies, delayed hypersensitivity reactions have been uncommon and
have occurred after Remicade&#8209;free intervals of less than 1&nbsp;year (see
sections&nbsp;4.4 and 4.8). The safety and efficacy of re&#8209;administration
after a Remicade&#8209;free interval of more than 16&nbsp;weeks has not been
established. This applies to both Crohn&#8217;s disease patients and rheumatoid
arthritis patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Re</span></u><u><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>administration for ulcerative colitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of re&#8209;administration,
other than every 8&nbsp;weeks, has not been established </span><span
lang=EN-GB>(see sections&nbsp;4.4 and 4.8)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Re</span></u><u><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>administration for ankylosing
spondylitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of re&#8209;administration,
other than every 6 to 8&nbsp;weeks, has not been established </span><span
lang=EN-GB>(see sections&nbsp;4.4 and 4.8)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Re</span></u><u><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>administration for psoriatic arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of re&#8209;administration,
other than every 8&nbsp;weeks, has not been established </span><span
lang=EN-GB>(see sections&nbsp;4.4 and 4.8)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Re</span></u><u><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>administration for psoriasis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Limited experience from re&#8209;treatment
with one single Remicade dose in psoriasis after an interval of 20&nbsp;weeks
suggests reduced efficacy and a higher incidence of mild to moderate infusion
reactions when compared to the initial induction regimen (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited experience from re</span><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>treatment following disease flare by
a re&#8209;induction regimen suggests a higher incidence of infusion reactions,
including serious ones, when compared to 8&#8209;weekly maintenance treatment
(see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Re</span></u><u><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>administration across indications</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In case maintenance therapy is interrupted,
and there is a need to restart treatment, use of a re&#8209;induction regimen
is not recommended (see section&nbsp;4.8). In this situation, Remicade should
be re&#8209;initiated as a single dose followed by the maintenance dose
recommendations described above.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Specific studies of Remicade in elderly
patients have not been conducted. No major age&#8209;related differences in
clearance or volume of distribution were observed in clinical studies. No dose
adjustment is required (see section&nbsp;5.2). For more information about the
safety of Remicade in elderly patients (see sections&nbsp;4.4 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
and/or hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Remicade has not been studied in these
patient populations. No dose recommendations can be made (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Crohn&#8217;s
disease (6 to 17&nbsp;years)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous infusion
followed by additional 5&nbsp;mg/kg infusion doses at 2 and 6&nbsp;weeks after
the first infusion, then every 8&nbsp;weeks thereafter. Available data do not
support further infliximab treatment in children and adolescents not responding
within the first 10&nbsp;weeks of treatment (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some patients may require a shorter dosing
interval to maintain clinical benefit, while for others a longer dosing
interval may be sufficient. Patients who have had their dose interval shortened
to less than 8&nbsp;weeks may be at greater risk for adverse reactions.
Continued therapy with a shortened interval should be carefully considered in
those patients who show no evidence of additional therapeutic benefit after a
change in dosing interval.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade have
not been studied in children with Crohn&#8217;s disease below the age of 6&nbsp;years.
Currently available pharmacokinetic data are described in section&nbsp;5.2 but
no recommendation on a posology can be made in children younger than 6&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Ulcerative
colitis (6 to 17&nbsp;years)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>5&nbsp;mg/kg given as an intravenous
infusion followed by additional 5&nbsp;mg/kg infusion doses at 2 and 6&nbsp;weeks
after the first infusion, then every 8&nbsp;weeks thereafter. Available data do
not support further infliximab treatment in paediatric patients not responding
within the first 8&nbsp;weeks of treatment (see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade have
not been studied in children with ulcerative colitis below the age of 6&nbsp;years.
Currently available pharmacokinetic data are described in section&nbsp;5.2 but
no recommendation on a posology can be made in children younger than 6&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Psoriasis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade in
children and adolescents younger than 18&nbsp;years for the indication of psoriasis
have not been established. Currently available data are described in section&nbsp;5.2
but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Juvenile
idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade in children
and adolescents younger than 18&nbsp;years for the indications of juvenile
idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not
been established. Currently available data are described in section&nbsp;5.2
but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Juvenile
rheumatoid arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade in
children and adolescents younger than 18&nbsp;years for the indication of juvenile
rheumatoid arthritis have not been established. Currently available data</span><span
lang=EN-GB> are</span><span lang=EN-GB> described in sections&nbsp;4.8&nbsp;and
5.2 but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Method
of administration</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Remicade should be administered
intravenously over a 2&nbsp;hour period. All patients administered Remicade are
to be observed for at least 1&#8209;2&nbsp;hours post&#8209;infusion for acute
infusion&#8209;related reactions. Emergency equipment, such as adrenaline,
antihistamines, corticosteroids and an artificial airway must be available.
Patients may be pre&#8209;treated with e.g., an antihistamine, hydrocortisone
and/or paracetamol and infusion rate may be slowed in order to decrease the
risk of infusion&#8209;related reactions especially if infusion&#8209;related
reactions have occurred previously (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Shortened
infusions across adult indications</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In carefully selected adult patients who have
tolerated at least 3</span><span lang=EN-GB>&nbsp;initial 2&#8209;hour
infusions of Remicade (induction phase) and are receiving maintenance therapy,
consideration may be given to administering subsequent infusions over a period
of not less than 1&nbsp;hour.</span><span lang=EN-GB> If an infusion reaction
occurs in association with a shortened infusion, a slower infusion rate may be
considered for future infusions if treatment is to be continued. Shortened
infusions at doses &gt;&nbsp;6&nbsp;mg/kg have not been studied (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For preparation and administration instructions,
see section&nbsp;6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance,
to other murine proteins, or to any of the excipients listed in
section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with tuberculosis or other severe
infections such as sepsis, abscesses, and opportunistic infections (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with moderate or severe heart
failure (NYHA class III/IV) (see sections&nbsp;4.4 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the tradename and the batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infusion
reactions and hypersensitivity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab has been associated with acute
infusion&#8209;related reactions, including anaphylactic shock, and delayed
hypersensitivity reactions (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Acute infusion reactions including
anaphylactic reactions may develop during (within seconds) or within a few
hours following infusion. If acute infusion reactions occur, the infusion must
be interrupted immediately. Emergency equipment, such as adrenaline,
antihistamines, corticosteroids and an artificial airway must be available.
Patients may be pre&#8209;treated with e.g., an antihistamine, hydrocortisone
and/or paracetamol to prevent mild and transient effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>Antibodies to infliximab may develop and
have been associated with an increased frequency of infusion reactions. A low
proportion of the infusion reactions was serious allergic reactions. An
association between development of antibodies to infliximab and reduced
duration of response has also been observed. Concomitant administration of
immunomodulators has been associated with lower incidence of antibodies to
infliximab and a reduction in the frequency of infusion reactions. The effect
of concomitant immunomodulator therapy was more profound in episodically&#8209;treated
patients than in patients given maintenance therapy. Patients who discontinue
immunosuppressants prior to or during Remicade treatment are at greater risk of
developing these antibodies. Antibodies to infliximab cannot always be detected
in serum samples. If serious reactions occur, symptomatic treatment must be
given and further Remicade infusions must not be administered (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies, delayed
hypersensitivity reactions have been reported. Available data suggest an
increased risk for delayed hypersensitivity with increasing Remicade&#8209;free
interval. Patients should be advised to seek immediate medical advice if they
experience any delayed adverse reaction (see section&nbsp;4.8). If patients are
re&#8209;treated after a prolonged period, they must be closely monitored for
signs and symptoms of delayed hypersensitivity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients must be monitored closely for
infections including tuberculosis before, during and after treatment with
Remicade. Because the elimination of infliximab may take up to six months,
monitoring should be continued throughout this period. Further treatment with
Remicade must not be given if a patient develops a serious infection or sepsis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Caution should be
exercised when considering the use of Remicade in patients with chronic
infection or a history of recurrent infections, including concomitant
immunosuppressive therapy. Patients should be advised of and avoid exposure to
potential risk factors for infection as appropriate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tumour necrosis
factor alpha (<a name="OLE_LINK5">TNF</a></span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB>) mediates
inflammation and modulates cellular immune responses. Experimental data show
that TNF</span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB> is essential for the clearing of intracellular infections. Clinical
experience shows that host defence against infection is compromised in some
patients treated with infliximab.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It should be
noted that suppression of TNF</span><sub><span lang=EN-GB style='font-family:
Symbol'>a</span></sub><span lang=EN-GB> may mask symptoms of infection such as
fever.</span><span lang=EN-GB> Early recognition of atypical clinical
presentations of serious infections </span><span lang=EN-GB>and of typical clinical
presentation of rare and unusual infections </span><span lang=EN-GB>is critical
in order to minimise delays in diagnosis and treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients taking TNF&#8209;blockers are more
susceptible to serious infections.</span></p>

<p class=MsoNormal><span lang=EN-GB>Tuberculosis, bacterial infections, </span><span
lang=EN-GB>including sepsis and pneumonia</span><span lang=EN-GB>, invasive
fungal, viral, and other opportunistic infections</span><span lang=EN-GB> have
been observed in patients treated with infliximab. Some of these infections
have been fatal</span><span lang=EN-GB>; </span><span lang=EN-GB>the most
frequently reported opportunistic infections with a mortality rate of
&gt;&nbsp;5% include pneumocystosis, candidiasis, listeriosis and aspergillosis</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who develop a new infection while
undergoing treatment with Remicade, should be monitored closely and undergo a
complete diagnostic evaluation. Administration of Remicade should be discontinued
if a patient develops a new serious infection or sepsis, and appropriate
antimicrobial or antifungal therapy should be initiated until the infection is
controlled.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Tuberculosis</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of active
tuberculosis in patients receiving Remicade. It should be noted that in the
majority of these reports tuberculosis was extrapulmonary, presenting as either
local or disseminated disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Before starting treatment with Remicade,
all patients must be evaluated for both active and inactive (&#8216;latent&#8217;)
tuberculosis. This evaluation should include a detailed medical history with
personal history of tuberculosis or possible previous contact with tuberculosis
and previous and/or current immunosuppressive therapy. Appropriate screening
tests (e.g. tuberculin skin test, chest X&#8209;ray, and/or Interferon Gamma
Release Assay), should be performed in all patients (local recommendations may
apply). It is recommended that t<span style='layout-grid-mode:line'>he conduct
of these tests should be recorded in the </span>patient&#8217;s reminder card.
Prescribers are reminded of the risk of false negative tuberculin skin test
results, especially in patients who are severely ill or immunocompromised<span
style='layout-grid-mode:line'>.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>If active
tuberculosis is diagnosed, Remicade therapy must not be initiated (see section&nbsp;4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If latent tuberculosis is suspected, a
physician with expertise in the treatment of tuberculosis should be consulted.
In all situations described below, the benefit/risk balance of Remicade therapy
should be very carefully considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If inactive (&#8216;latent&#8217;)
tuberculosis is diagnosed, treatment for latent tuberculosis must be started
with antituberculosis therapy before the initiation of Remicade, and in
accordance with local recommendations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients who have several or significant
risk factors for tuberculosis and have a negative test for latent tuberculosis,
antituberculosis therapy should be considered before the initiation of
Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Use of antituberculosis therapy should also
be considered before the initiation of Remicade in patients with a past history
of latent or active tuberculosis in whom an adequate course of treatment cannot
be confirmed.</span></p>

<p class=MsoNormal><span lang=EN-GB>Some cases of active tuberculosis have been
reported in patients treated with Remicade during and after treatment for
latent tuberculosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients should be informed to seek
medical advice if signs/symptoms suggestive of tuberculosis</span><span
lang=EN-GB> (e.g. persistent cough, wasting/weight loss, low&#8209;grade fever)
appear during or after Remicade treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Invasive
fungal infections</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In patients treated with Remicade, an
invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis,
histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they
develop a serious systemic illness</span><span lang=EN-GB>, and a physician
with expertise in the diagnosis and treatment of invasive fungal infections
should be consulted at an early stage when investigating these patients</span><span
lang=EN-GB>. Invasive fungal infections may present as disseminated rather than
localised disease, and antigen and antibody testing may be negative in some
patients with active infection. Appropriate empiric antifungal therapy should
be considered while a diagnostic workup is being performed taking into account
both the risk for severe fungal infection and the risks of antifungal therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients who have resided in or
travelled to regions where invasive fungal infections such as histoplasmosis,
coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of
Remicade treatment should be carefully considered before initiation of Remicade
therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Fistulising
Crohn&#8217;s disease</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients with fistulising Crohn&#8217;s
disease with acute suppurative fistulas must not initiate Remicade therapy
until a source for possible infection, specifically abscess, has been excluded
(see section&nbsp;4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatitis
B (HBV) reactivation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reactivation of hepatitis B has occurred in
patients receiving a TNF&#8209;antagonist including infliximab, who are chronic
carriers of this virus. Some cases have had fatal outcome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be tested for HBV infection
before initiating treatment with Remicade. For patients who test positive for
HBV infection, consultation with a physician with expertise in the treatment of
hepatitis B is recommended.</span><span lang=EN-GB> Carriers of HBV who require
treatment with Remicade should be closely monitored for signs and symptoms of
active HBV infection throughout therapy and for several months following
termination of therapy. Adequate data of treating patients who are carriers of
HBV with antiviral therapy in conjunction with TNF&#8209;antagonist therapy to
prevent HBV reactivation are not available. In patients who develop HBV
reactivation, Remicade should be stopped and effective antiviral therapy with
appropriate supportive treatment should be initiated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
events</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Cases of jaundice and non&#8209;infectious
hepatitis, some with features of autoimmune hepatitis, have been observed in
the post&#8209;marketing experience of Remicade. Isolated cases of liver
failure resulting in liver transplantation or death have occurred. Patients
with symptoms or signs of liver dysfunction should be evaluated for evidence of
liver injury. If jaundice and/or ALT elevations &#8805;&nbsp;5&nbsp;times the
upper limit of normal develop(s), Remicade should be discontinued, and a
thorough investigation of the abnormality should be undertaken.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Concurrent
administration of TNF&#8209;alpha inhibitor and anakinra</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Serious infections </span><span lang=EN-GB>and
neutropenia </span><span lang=EN-GB>were seen in clinical studies with
concurrent use of anakinra and another TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB>&#8209;blocking
agent, etanercept, with no added clinical benefit compared to etanercept alone.
Because of the nature of the adverse reactions seen with combination of
etanercept and anakinra therapy, similar toxicities may also result from the
combination of anakinra and other TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB>&#8209;blocking
agents. Therefore, the combination of Remicade and anakinra is not recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Concurrent
administration of TNF&#8209;alpha inhibitor and abatacept</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies concurrent
administration of TNF&#8209;antagonists and abatacept has been associated with
an increased risk of infections including serious infections compared to TNF&#8209;antagonists
alone, without increased clinical benefit. The combination of Remicade and
abatacept is not recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Concurrent
administration with other biological therapeutics</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There is insufficient information regarding
the concomitant use of infliximab with other biological therapeutics used to
treat the same conditions as infliximab. The concomitant use of infliximab with
these biologics is not recommended </span><span lang=EN-GB>because of the
possibility of an increased risk of infection, and other potential
pharmacological interactions.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Switching
between biological DMARDS</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Care should be taken and patients should
continue to be monitored when switching from one biologic to another, since
overlapping biological activity may further increase the risk for adverse reactions,
including infection.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk502758333"><u><span
lang=EN-GB>Vaccinations</span></u></a><a name="_Hlk502758339"></a></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that patients, if possible,
be brought up to date with all vaccinations in agreement with current
vaccination guidelines prior to initiating Remicade therapy. Patients on
infliximab may receive concurrent vaccinations, except for live vaccines (see
sections&nbsp;4.5 and&nbsp;4.6).</span></p>

<p class=MsoNormal><a name="_Hlk503547227"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal><span lang=EN-GB>In a subset of 90 adult patients with
rheumatoid arthritis from the ASPIRE study a similar proportion of patients in
each treatment group (methotrexate plus: placebo [n&nbsp;=&nbsp;17],
3&nbsp;mg/kg [n&nbsp;=&nbsp;27] or 6&nbsp;mg/kg Remicade [n&nbsp;=&nbsp;46])
mounted an effective two-fold increase in titers to a polyvalent pneumococcal
vaccine, indicating that Remicade did not interfere with T-cell independent
humoral immune responses. However, studies from the published literature in
various indications (e.g. rheumatoid arthritis, psoriasis, Crohn&#8217;s
disease) suggest that non-live vaccinations received during treatment with
anti-TNF therapies, including Remicade, may elicit a lower immune response than
in patients not receiving anti-TNF therapy.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Live
vaccines/therapeutic infectious agents</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In patients receiving anti&#8209;TNF
therapy, limited data are available on the response to vaccination with live
vaccines or on the secondary transmission of infection by live vaccines. Use of
live vaccines can result in clinical infections, including disseminated infections.
The concurrent administration of live vaccines with Remicade is not
recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>infants exposed <i>in
utero</i> to infliximab</span><span lang=EN-GB>, fatal outcome due to
disseminated Bacillus Calmette&#8209;Gu&eacute;rin (BCG) infection has been
reported following administration of BCG vaccine after birth. At least a six
month waiting period following birth is recommended before the administration
of live vaccines to infants exposed <i>in utero </i>to infliximab (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other uses of therapeutic infectious agents
such as live attenuated bacteria (e.g., BCG bladder instillation for the
treatment of cancer) could result in clinical infections, including
disseminated infections. It is recommended that therapeutic infectious agents
not be given concurrently with Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Autoimmune
processes</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The relative deficiency of TNF</span><sub><span
lang=EN-GB style='font-family:Symbol'>a</span></sub><span lang=EN-GB> caused by
anti&#8209;TNF therapy may result in the initiation of an autoimmune process.
If a patient develops symptoms suggestive of a lupus&#8209;like syndrome
following treatment with Remicade and is positive for antibodies against double&#8209;stranded
DNA, further treatment with Remicade must not be given (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Neurological
events</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Use of TNF&#8209;blocking agents, including
infliximab, has been associated with cases of new onset or exacerbation of
clinical symptoms and/or radiographic evidence of central nervous system
demyelinating disorders, including multiple sclerosis, and peripheral
demyelinating disorders, including Guillain&#8209;Barr&eacute; syndrome. In
patients with pre&#8209;existing or recent onset of demyelinating disorders, the
benefits and risks of anti&#8209;TNF treatment should be carefully considered
before initiation of Remicade therapy. Discontinuation of Remicade should be
considered if these disorders develop.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Malignancies
and lymphoproliferative disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the
controlled portions of clinical studies of TNF&#8209;blocking agents, more
cases of malignancies including lymphoma have been observed among patients
receiving a TNF blocker compared with control patients. During clinical studies
of Remicade across all approved indications the incidence of lymphoma in
Remicade&#8209;treated patients was higher than expected in the general
population, but the occurrence of lymphoma was rare. </span><span lang=EN-GB>In
the post&#8209;marketing setting, cases of leukaemia have been reported in
patients treated with a TNF&#8209;antagonist. </span><span lang=EN-GB>There is
an increased background risk for lymphoma and leukaemia in rheumatoid arthritis
patients with long&#8209;standing, highly active, inflammatory disease, which
complicates risk estimation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In an exploratory clinical study evaluating
the use of Remicade in patients with moderate to severe chronic obstructive
pulmonary disease (COPD), more malignancies were reported in Remicade&#8209;treated
patients compared with control patients. All patients had a history of heavy
smoking. Caution should be exercised in considering treatment of patients with
increased risk for malignancy due to heavy smoking.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>With the current knowledge, a risk for the
development of lymphomas or other malignancies in patients treated with a TNF&#8209;blocking
agent cannot be excluded (see section&nbsp;4.8). </span><span lang=EN-GB>Caution
should be exercised when considering TNF&#8209;blocking therapy for patients
with a history of malignancy or when considering continuing treatment in
patients who develop a malignancy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Caution should also be exercised in
patients with psoriasis and a medical history of extensive immunosuppressant
therapy or prolonged PUVA treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Malignancies, some fatal, have been
reported among children, adolescents and young adults (up to 22&nbsp;years of
age) treated with TNF&#8209;blocking agents (initiation of therapy
&#8804;&nbsp;18&nbsp;years of age), including Remicade in the post&#8209;marketing
setting. Approximately half the cases were lymphomas. The other cases
represented a variety of different malignancies and included rare malignancies
usually associated with immunosuppression. A risk for the development of
malignancies in patients treated with TNF&#8209;blockers cannot be excluded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Post</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>marketing cases of hepatosplenic T</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>cell lymphoma (HSTCL) have been reported in patients </span><span
lang=EN-GB>treated with<b> </b>TNF</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>blocking agents including infliximab.&nbsp;This rare type of T</span><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>cell lymphoma has a very aggressive
disease course and is usually fatal. Almost all patients had received treatment
with AZA or 6</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>MP
concomitantly with or immediately prior to a TNF</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>blocker. The vast majority of Remicade cases have occurred in
patients </span><span lang=EN-GB>with Crohn&#8217;s disease </span><span
lang=EN-GB>or ulcerative colitis and most were reported in adolescent or young
adult males.</span><span lang=EN-GB> The potential risk with the combination of
AZA or 6</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>MP and Remicade
should be carefully considered. A risk for the development for hepatosplenic T</span><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>cell lymphoma in patients treated
with Remicade cannot be excluded (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Melanoma and Merkel cell carcinoma have
been reported in patients treated with TNF blocker therapy, including Remicade
(see section&nbsp;4.8). Periodic skin examination is recommended, particularly for
patients with risk factors for skin cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A population</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>based retrospective cohort study using data from Swedish national
health registries found an increased incidence of cervical cancer in women with
rheumatoid arthritis treated with infliximab compared to biologics</span><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>na&iuml;ve patients or the general
population, including those over 60&nbsp;years of age. Periodic screening
should continue in women treated with Remicade, including those over
60&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients with ulcerative colitis who
are at increased risk for dysplasia or colon carcinoma (for example, patients
with long</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>standing
ulcerative colitis or primary sclerosing cholangitis), or who had a prior
history of dysplasia or colon carcinoma should be screened for dysplasia at
regular intervals before therapy and throughout their disease course. This
evaluation should include colonoscopy and biopsies per local recommendations. Current
data do not indicate that infliximab treatment influences the risk for
developing dysplasia or colon cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Since the possibility of increased risk of
cancer development in patients with newly diagnosed dysplasia treated with
Remicade is not established, the risk and benefits of continued therapy to the
individual patients should be carefully considered by the clinician.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Heart
failure</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade should be used with caution in
patients with mild heart failure (NYHA class I/II). Patients should be closely
monitored and Remicade must not be continued in patients who develop new or
worsening symptoms of heart failure (see sections&nbsp;4.3 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Haematologic
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of pancytopenia,
leucopenia, neutropenia, and thrombocytopenia in patients receiving TNF</span><span
lang=EN-GB>&#8209;</span><span lang=EN-GB>blockers, including Remicade. </span><span
lang=EN-GB>All patients should be advised to seek immediate medical attention
if they develop signs and symptoms suggestive of blood dyscrasias (e.g.
persistent fever, bruising, bleeding, pallor). Discontinuation of Remicade
therapy should be considered in patients with confirmed significant haematologic
abnormalities.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Others</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There is limited safety experience of
Remicade treatment in patients who have undergone surgical procedures,
including arthroplasty. The long half&#8209;life of infliximab should be taken
into consideration if a surgical procedure is planned. A patient who requires
surgery while on Remicade should be closely monitored for infections, and
appropriate actions should be taken.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Failure to respond to treatment for
Crohn&#8217;s disease may indicate the presence of a fixed fibrotic stricture
that may require surgical treatment. There is no evidence to suggest that
infliximab worsens or causes fibrotic strictures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>The incidence
of serious infections in Remicade</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB style='layout-grid-mode:line'>treated patients 65&nbsp;years and
older was greater than in those under 65&nbsp;years of age. </span><span
lang=EN-GB>Some of those had a fatal outcome.</span><span lang=EN-GB
style='layout-grid-mode:line'> </span><span lang=EN-GB>Particular attention
regarding the risk for infection should be paid when treating the elderly (see
section&nbsp;4.8)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB>Paediatric population</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In clinical
studies, infections have been reported in a higher proportion of paediatric
patients compared to adult patients (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that paediatric patients,
if possible, be brought up to date with all vaccinations in agreement with
current vaccination guidelines prior to initiating Remicade therapy. Paediatric
patients on infliximab may receive concurrent vaccinations, except for live
vaccines (see sections&nbsp;4.5 and&nbsp;4.6).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Malignancies and lymphoproliferative disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Malignancies,
some fatal, have been reported among children, adolescents and young adults (up
to 22&nbsp;years of age) treated with TNF&#8209;blocking agents (initiation of
therapy &#8804;&nbsp;18&nbsp;years of age), including Remicade in the post&#8209;marketing
setting. Approximately half the cases were lymphomas. The other cases
represented a variety of different malignancies and included rare malignancies
usually associated with immunosuppression. A risk for the development of
malignancies in children and adolescents treated with TNF&#8209;blockers cannot
be excluded.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Post&#8209;marketing cases of hepatosplenic
T&#8209;cell lymphoma have been reported in patients </span><span lang=EN-GB>treated
with<b> </b></span><span lang=EN-GB>TNF&#8209;blocking agents </span><span
lang=EN-GB>including infliximab.&nbsp;This rare type of T&#8209;cell lymphoma
has a very aggressive disease course and is usually fatal. </span><span
lang=EN-GB>Almost all patients had received treatment with AZA or 6&#8209;MP
concomitantly with or immediately prior to a TNF&#8209;blocker. </span><span
lang=EN-GB>The vast majority of Remicade cases have occurred in patients </span><span
lang=EN-GB>with Crohn&#8217;s disease </span><span lang=EN-GB>or ulcerative
colitis and most were reported in adolescent or young adult males.</span><span
lang=EN-GB> The potential risk with the combination of AZA or 6&#8209;MP and
Remicade should be carefully considered. A risk for the development for
hepatosplenic T&#8209;cell lymphoma in patients treated with Remicade cannot be
excluded (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sodium
content</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade contains less than 1&nbsp;mmol
sodium (23&nbsp;mg) per dose, i.e. essentially &#8216;sodium&#8209;free&#8217;.
Remicade is however, diluted in sodium chloride 9&nbsp;mg/ml (0.9%) solution
for infusion. This should be taken into consideration for patients on a
controlled sodium diet (see section&nbsp;6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No interaction studies have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB
style='layout-grid-mode:line'>rheumatoid arthritis, psoriatic arthritis and
Crohn's disease</span><span lang=EN-GB> patients, there are indications that
concomitant use of methotrexate and other immunomodulators reduces the
formation of antibodies against infliximab and increases the plasma
concentrations of infliximab. However, the results are uncertain due to
limitations in the methods used for serum analyses of infliximab and antibodies
against infliximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Corticosteroids do not appear to affect the
pharmacokinetics of infliximab to a clinically relevant extent.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The combination of Remicade with other
biological therapeutics used to treat the same conditions as Remicade, including
anakinra and abatacept, is not recommended (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that live vaccines not be
given concurrently with Remicade. It is also recommended that live vaccines not
be given to infants after <i>in utero</i> exposure to infliximab for at least
6&nbsp;months following birth (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that therapeutic
infectious agents not be given concurrently with Remicade (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and
lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential should
consider the use of adequate contraception to prevent pregnancy and continue
its use for at least 6&nbsp;months after the last Remicade treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The moderate number of prospectively
collected pregnancies exposed to infliximab resulting in live birth with known
outcomes, including approximately 1100&nbsp;exposed during the first trimester,
</span><span lang=EN-GB>does not indicate an increase in the rate of
malformation in the newborn.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Based on an observational study from
Northern Europe, an increased risk (OR, 95% CI; p&#8209;value) for C&#8209;section
(1.50, 1.14&#8209;1.96; p&nbsp;=&nbsp;0.0032), preterm birth (1.48, 1.05&#8209;2.09;
p&nbsp;=&nbsp;0.024), small for gestational age (2.79, 1.54&#8209;5.04; p&nbsp;=&nbsp;0.0007),
and low birth weight (2.03, 1.41&#8209;2.94; p&nbsp;=&nbsp;0.0002) was observed
in women exposed during pregnancy to infliximab (with or without
immunomodulators/corticosteroids, 270&nbsp;pregnancies) as compared to women
exposed to immunomodulators and/or corticosteroids only (6,460&nbsp;pregnancies).
The potential contribution of exposure to infliximab and/or the severity of the
underlying disease in these outcomes remains unclear.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to its inhibition of TNF</span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>, infliximab
administered during pregnancy could affect normal immune responses in the
newborn. In a developmental toxicity study conducted in mice using an analogous
antibody that selectively inhibits the functional activity of mouse TNF</span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>, there was no
indication of maternal toxicity, embryotoxicity or teratogenicity (see section&nbsp;5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The available clinical experience is
limited. Infliximab should only be used during pregnancy if clearly needed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab crosses the placenta and has
been detected in the serum of infants up to 6&nbsp;months following birth.
After <i>in utero</i> exposure to infliximab, infants may be at increased risk
of infection, including serious disseminated infection that can become fatal.
Administration of live vaccines (e.g.&nbsp;BCG vaccine) to infants exposed to
infliximab <i>in utero</i> is not recommended for at least 6&nbsp;months after
birth (see sections&nbsp;4.4 and 4.5). Cases of agranulocytosis have also been reported
(see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether infliximab is
excreted in human milk or absorbed systemically after ingestion. Because human
immunoglobulins are excreted in milk, women must not breast feed for at least 6&nbsp;months
after Remicade treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There are insufficient preclinical data to
draw conclusions on the effects of infliximab on fertility and general
reproductive function (see section&nbsp;5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade may have a minor influence on the
ability to drive and use machines. Dizziness may occur following administration
of Remicade (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Summary
of the safety profile</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Upper respiratory tract infection was the
most common adverse drug reaction (ADR) reported in clinical trials, occurring
in 25.3% of infliximab&#8209;treated patients compared with 16.5% of control
patients</span><span lang=EN-GB>. The most serious ADRs associated with the use
of TNF blockers that have been reported for Remicade include HBV reactivation,
CHF (congestive heart failure), serious infections (including sepsis,
opportunistic infections and TB), serum sickness (delayed hypersensitivity
reactions), haematologic reactions, systemic lupus erythematosus/lupus&#8209;like
syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia,
Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid&#8209;like
reaction, intestinal or perianal abscess (in Crohn&#8217;s disease), and
serious infusion reactions (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tabulated
list of adverse reactions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Table&nbsp;1 lists ADRs based on experience
from clinical studies as well as adverse reactions, some with fatal outcome,
reported from post&#8209;marketing experience. Within the organ system classes,
adverse reactions are listed under headings of frequency using the following
categories: very common (&#8805;&nbsp;1/10); common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10);
uncommon&nbsp;(&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000), not known (cannot be
estimated from the available data). Within each frequency grouping, undesirable
effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;1</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Undesirable effects in clinical studies and from
  post&#8209;marketing experience</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Very
  Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Viral infection (e.g. influenza, herpes
  virus infection).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Bacterial infections (e.g. sepsis,
  cellulitis, abscess). </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Tuberculosis, fungal infections (e.g.
  candidiasis, onychomycosis).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Meningitis, opportunistic infections
  (such as invasive fungal infections [pneumocystosis, histoplasmosis,
  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial
  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral
  infections [cytomegalovirus]), parasitic infections, hepatitis B
  reactivation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vaccine breakthrough infection (after <i>in
  utero </i>exposure to infliximab)*.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Neoplasms
  benign, malignant and unspecified (including cysts and polyps)</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Lymphoma,</span><span lang=EN-GB> non&#8209;Hodgkin&#8217;s
  lymphoma, Hodgkin&#8217;s disease, leukaemia, melanoma, cervical cancer.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatosplenic T&#8209;cell lymphoma
  (primarily in adolescents and young adult males with Crohn&#8217;s disease or
  ulcerative colitis), Merkel cell carcinoma<span class=msoIns><ins
  cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
  datetime="2020-08-18T11:09">, Kaposi&#8217;s sarcoma</ins></span>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Neutropenia, leucopenia, anaemia,
  lymphadenopathy.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Thrombocytopenia, lymphopenia, lymphocytosis.
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Agranulocytosis (including infants
  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,
  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Allergic respiratory symptom<span
  style='layout-grid-mode:line'>.</span></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anaphylactic reaction, lupus&#8209;like
  syndrome, serum sickness or<span style='layout-grid-mode:line'> serum
  sickness&#8209;like reaction</span>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid' style='page-break-inside:avoid !msorm'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.4pt 0in 5.4pt !msorm'>
  <p class=MsoNormal><span lang=EN-GB>Anaphylactic shock, vasculitis, sarcoid&#8209;like
  reaction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Psychiatric
  disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Depression, insomnia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR>Amnesia, agitation, confusion, somnolence,
  nervousness.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Apathy.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Very
  common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Headache.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vertigo, dizziness, hypoaesthesia,
  paraesthesia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Seizure, neuropathy.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Transverse myelitis, central nervous
  system demyelinating disorders (multiple sclerosis&#8209;like disease and
  optic neuritis), peripheral demyelinating disorders (such as Guillain&#8209;Barr&eacute;
  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal
  motor neuropathy).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cerebrovascular accidents in close temporal
  association with infusion.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Conjunctivitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Keratitis, periorbital oedema, hordeolum.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Endophthalmitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Transient visual loss occurring during or
  within 2&nbsp;hours of infusion.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Tachycardia, palpitation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cardiac failure (new onset or worsening),
  arrhythmia, syncope, bradycardia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cyanosis, pericardial effusion.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Myocardial ischaemia/myocardial
  infarction</span><span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hypotension, hypertension, ecchymosis,
  hot flush, flushing.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Peripheral ischaemia, thrombophlebitis,
  haematoma.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Circulatory failure, petechia, vasospasm.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Very
  common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Upper respiratory tract infection, sinusitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Lower respiratory tract infection (e.g.
  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pulmonary oedema, bronchospasm, pleurisy,
  pleural effusion.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Interstitial lung disease (including
  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Very
  common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Abdominal pain, nausea.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal haemorrhage, diarrhoea,
  dyspepsia, gastroesophageal reflux, constipation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Intestinal perforation, intestinal stenosis,
  diverticulitis, pancreatitis, cheilitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatic function abnormal, transaminases
  increased.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatitis, hepatocellular damage,
  cholecystitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Autoimmune hepatitis, jaundice.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Liver failure.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Skin and subcutaneous
  tissue disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>New onset or worsening psoriasis
  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,
  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Bullous eruption, seborrhoea, rosacea,
  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis, Stevens&#8209;Johnson
  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis
  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid
  reactions.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Not
  known:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Worsening of symptoms of dermatomyositis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Arthralgia, myalgia, back pain.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Renal and
  urinary disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Urinary tract infection.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pyelonephritis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reproductive
  system and breast disorders</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vaginitis.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Very
  common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Infusion&#8209;related reaction, pain.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Common:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Chest pain, fatigue, fever, injection
  site reaction, chills, oedema.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Impaired healing.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Granulomatous lesion.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Uncommon:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Autoantibody positive.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=216 valign=top style='width:162.25pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB>Rare:</span></p>
  </td>
  <td width=388 valign=top style='width:291.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Complement factor abnormal.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=2 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB>*&nbsp;&nbsp; </span><span lang=EN-GB style='font-size:9.0pt'>including
  bovine tuberculosis (disseminated BCG infection), see section&nbsp;4.4</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse drug reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Infusion&#8209;related reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>An infusion&#8209;related
reaction was defined in clinical studies as any adverse event occurring during an
infusion or within 1&nbsp;hour after an infusion. In Phase III clinical
studies, 18% of infliximab&#8209;treated patients compared with 5% of placebo&#8209;treated
patients experienced an infusion&#8209;related reaction. Overall, a higher
proportion of patients receiving infliximab monotherapy experienced an infusion&#8209;related
reaction compared to patients receiving infliximab with concomitant immunomodulators.
Approximately 3% of patients discontinued treatment due to infusion&#8209;related
reactions and all patients recovered with or without medical therapy. Of
infliximab&#8209;treated patients who had an infusion reaction during the
induction period, through week&nbsp;6, 27% experienced an infusion reaction
during the maintenance period, week&nbsp;7 through week&nbsp;54. Of patients
who did not have an infusion reaction during the induction period, 9%
experienced an infusion reaction during the maintenance period.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In a clinical
study of patients with rheumatoid arthritis (ASPIRE), </span><span lang=EN-GB>infusions
were to be administered over 2&nbsp;hours for the first 3&nbsp;infusions. The
duration of subsequent infusions could be shortened to not less than
40&nbsp;minutes in patients who did not experience serious infusion reactions.
In this trial, </span><span lang=EN-GB>sixty six percent of the patients (686
out of 1,040) received at least one shortened infusion of 90&nbsp;minutes or
less and 44% of the patients (454 out of 1,040) received at least one shortened
infusion of 60&nbsp;minutes or less. Of the infliximab</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>treated patients who received at least one shortened infusion,
infusion&#8209;related reactions occurred in 15% of patients and serious
infusion reactions occurred in 0.4% of patients.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a clinical study of patients with
Crohn&#8217;s disease (SONIC), infusion&#8209;related reactions occurred in
16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of
patients receiving infliximab in combination with AZA, and 5.6% (9/161) of
patients receiving AZA monotherapy. </span><span lang=EN-GB>One</span><span
lang=EN-GB> serious infusion reaction (&lt;&nbsp;1%) occurred in a patient on
infliximab monotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In post&#8209;marketing
experience, cases of anaphylactic&#8209;like reactions, including
laryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been
associated with Remicade administration </span><span lang=EN-GB>(see
section&nbsp;4.4)</span><span lang=EN-GB style='layout-grid-mode:line'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of transient visual loss occurring
during or within 2&nbsp;hours of Remicade infusion have been reported. Events
(some fatal) of m</span><span lang=EN-GB>yocardial ischaemia/infarction and
arrhythmia have been reported, some in close temporal association with infusion
of infliximab; </span><span lang=EN-GB>cerebrovascular accidents have also been
reported in close temporal association with infusion of infliximab</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infusion
reactions following re&#8209;administration of Remicade</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A clinical study in patients with moderate to
severe psoriasis was designed to assess the efficacy and safety of long&#8209;term
maintenance therapy versus re&#8209;treatment with an induction regimen of
Remicade (maximum of four infusions at 0, 2, 6 and 14&nbsp;weeks) following
disease flare. Patients did not receive any concomitant immunosuppressant
therapy. In the re&#8209;treatment arm, 4% (8/219) of patients experienced a
serious infusion reaction versus &lt;&nbsp;1% (1/222) on maintenance therapy.
The majority of serious infusion reactions occurred during the second infusion
at week&nbsp;2. The interval between the last maintenance dose and the first re&#8209;induction
dose ranged from 35&#8209;231&nbsp;days. Symptoms included, but were not
limited to, dyspnea, urticaria, facial oedema, and hypotension. In all cases,
Remicade treatment was discontinued and/or other treatment instituted with
complete resolution of signs and symptoms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Delayed
hypersensitivity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies delayed
hypersensitivity reactions have been uncommon and have occurred after Remicade&#8209;free
intervals of less than 1&nbsp;year. In the psoriasis studies, delayed
hypersensitivity reactions occurred early in the treatment course. Signs and
symptoms included myalgia and/or arthralgia with fever and/or rash, with some
patients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria,
sore throat and headache.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are insufficient data on the
incidence of delayed hypersensitivity reactions after Remicade&#8209;free
intervals of more than 1&nbsp;year but limited data from clinical studies
suggest an increased risk for delayed hypersensitivity with increasing Remicade&#8209;free
interval </span><span lang=EN-GB>(see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In a 1&#8209;year
clinical study with repeated infusions in patients with Crohn's disease (ACCENT
I study), the incidence of serum sickness&#8209;like reactions was 2.4%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immunogenicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients who developed antibodies to
infliximab were more likely (approximately 2&#8209;3&nbsp;fold) to develop
infusion&#8209;related reactions. Use of concomitant immunosuppressant agents
appeared to reduce the frequency of infusion&#8209;related reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies using single and multiple
infliximab doses ranging from 1 to 20&nbsp;mg/kg, antibodies to infliximab were
detected in 14% of&nbsp;patients with any immunosuppressant therapy, and in 24%
of&nbsp;patients without immunosuppressant therapy. In rheumatoid arthritis
patients who received the recommended repeated treatment dose regimens with
methotrexate, 8% of&nbsp;patients developed antibodies to infliximab. In
psoriatic arthritis patients who received 5&nbsp;mg/kg with and without
methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred
in 4% of patients receiving methotrexate and in 26% of patients not receiving
methotrexate at baseline). In Crohn's disease patients who received maintenance
treatment, antibodies to infliximab occurred overall in 3.3% of patients receiving
immunosuppressants and in 13.3% of patients not receiving immunosuppressants.
The antibody incidence was 2&#8209;3&nbsp;fold higher for patients treated
episodically. Due to methodological limitations, a negative assay did not
exclude the presence of antibodies to infliximab. Some patients who developed
high titres of antibodies to infliximab had evidence of reduced efficacy. In
psoriasis patients treated with infliximab as a maintenance regimen in the
absence of concomitant immunomodulators, approximately 28% developed antibodies
to infliximab (see section&nbsp;4.4: &#8220;Infusion reactions and
hypersensitivity&#8221;).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Tuberculosis, bacterial infections,
including sepsis and pneumonia, invasive fungal, viral, and other opportunistic
infections have been observed in patients receiving Remicade. Some of these
infections have been fatal; the most frequently reported opportunistic
infections </span><span lang=EN-GB>with a mortality rate of &gt;&nbsp;5% </span><span
lang=EN-GB>include pneumocystosis, candidiasis, listeriosis and aspergillosis
(see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies 36% of infliximab&#8209;treated
patients were treated for infections compared with 25% of placebo&#8209;treated
patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In rheumatoid arthritis clinical studies,
the incidence of serious infections including pneumonia was higher in
infliximab plus methotrexate&#8209;treated patients compared with methotrexate
alone especially at doses of 6&nbsp;mg/kg or greater (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In post&#8209;marketing spontaneous
reporting, infections are the most common serious adverse reaction. Some of the
cases have resulted in a fatal outcome. Nearly 50% of reported deaths have been
associated with infection. Cases of tuberculosis, sometimes fatal, including
miliary tuberculosis and tuberculosis with extra&#8209;pulmonary location have
been reported (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Malignancies and lymphoproliferative disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>In clinical studies with infliximab </span><span
lang=EN-GB>in which 5,780&nbsp;patients were treated,</span><span lang=EN-GB
style='layout-grid-mode:line'> representing </span><span lang=EN-GB>5,494</span><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;patient years, </span><span
lang=EN-GB>5&nbsp;</span><span lang=EN-GB style='layout-grid-mode:line'>cases
of lymphomas and </span><span lang=EN-GB>26&nbsp;non&#8209;lymphoma
malignancies</span><span lang=EN-GB style='layout-grid-mode:line'> were
detected as compared with </span><span lang=EN-GB>no lymphomas and 1&nbsp;non&#8209;lymphoma
malignancy</span><span lang=EN-GB style='layout-grid-mode:line'> in 1,600&nbsp;placebo&#8209;treated
patients representing</span><span lang=EN-GB> 941</span><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;patient years.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In long&#8209;term
safety follow&#8209;up of clinical studies with infliximab of up to 5&nbsp;years,
representing 6,234&nbsp;patients&#8209;years (3,210&nbsp;patients), 5&nbsp;cases
of lymphoma and 38&nbsp;cases of non&#8209;lymphoma malignancies were reported.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>Cases of malignancies, including lymphoma, have
also been reported in the post&#8209;marketing setting </span><span lang=EN-GB>(see
section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In an
exploratory clinical study involving patients with moderate to severe COPD who
were either current smokers or ex&#8209;smokers, 157&nbsp;adult patients were
treated with Remicade at doses similar to those used in rheumatoid arthritis
and Crohn&#8217;s disease. Nine of these patients developed malignancies,
including 1&nbsp;lymphoma. The median duration of follow&#8209;up was 0.8&nbsp;years
(incidence 5.7% [95% CI 2.65%&#8209;10.6%]. There was one reported malignancy
amongst 77&nbsp;control patients (median duration of follow&#8209;up 0.8&nbsp;years;
incidence 1.3% [95% CI 0.03%&#8209;7.0%]). The majority of the malignancies
developed in the lung or head and neck.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A population&#8209;based retrospective
cohort study found an increased incidence of cervical cancer in women with
rheumatoid arthritis treated with infliximab compared to biologics&#8209;na&iuml;ve
patients or the general population, including those over 60&nbsp;years of age
(see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, post&#8209;marketing cases of
hepatosplenic T&#8209;cell lymphoma have been reported in patients treated with
Remicade with the vast majority of cases occurring in Crohn&#8217;s disease </span><span
lang=EN-GB>and ulcerative colitis, and most of whom were adolescent or young
adult males</span><span lang=EN-GB> (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Heart
failure</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In a Phase II study aimed at evaluating
Remicade in CHF, higher incidence of mortality due to worsening of heart
failure were seen in patients treated with Remicade, especially those treated
with the higher dose of 10&nbsp;mg/kg (i.e. twice the maximum approved dose).
In this study 150&nbsp;patients with NYHA Class III&#8209;IV CHF (left
ventricular ejection fraction &#8804;&nbsp;35%) were treated with
3&nbsp;infusions of Remicade 5&nbsp;mg/kg, 10&nbsp;mg/kg, or placebo over 6&nbsp;weeks.
At 38&nbsp;weeks, 9 of 101&nbsp;patients treated with Remicade (2 at 5&nbsp;mg/kg
and 7 at 10&nbsp;mg/kg) died compared to one death among the 49&nbsp;patients
on placebo.</span></p>

<p class=MsoNormal><span lang=EN-GB>There have been post&#8209;marketing
reports of worsening heart failure, with and without identifiable precipitating
factors, in patients taking Remicade. There have also been post&#8209;marketing
reports of new onset heart failure, including heart failure in patients without
known pre&#8209;existing cardiovascular disease. Some of these patients have
been under 50&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatobiliary
events</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In clinical studies, mild or moderate
elevations of ALT and AST have been observed in patients receiving Remicade
without progression to severe hepatic injury. Elevations of ALT &#8805;&nbsp;5&nbsp;x&nbsp;Upper
Limit of Normal (ULN) have been observed (see Table&nbsp;2). Elevations of
aminotransferases were observed (ALT more common than AST) in a greater
proportion of patients receiving Remicade than in controls, both when Remicade
was given as monotherapy and when it was used in combination with other
immunosuppressive agents. Most aminotransferase abnormalities were transient;
however, a small number of patients experienced more prolonged elevations. In
general, patients who developed ALT and AST elevations were asymptomatic, and
the abnormalities decreased or resolved with either continuation or
discontinuation of Remicade, or modification of concomitant therapy.<i> </i>In
post&#8209;marketing surveillance, cases of jaundice and hepatitis, some with
features of autoimmune hepatitis, have been reported in patients receiving
Remicade (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=611 colspan=9 valign=top style='width:457.9pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;2</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Proportion of patients with increased ALT activity
  in clinical studies</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 rowspan=2 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Indication</span></p>
  </td>
  <td width=133 colspan=2 valign=top style='width:99.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Number of patients<sup>3</sup></span></p>
  </td>
  <td width=133 colspan=2 valign=top style='width:99.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median follow&#8209;up (wks)<sup>4</sup></span></p>
  </td>
  <td width=131 colspan=2 valign=top style='width:98.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;3&nbsp;x ULN</span></p>
  </td>
  <td width=134 colspan=2 valign=top style='width:100.25pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;5&nbsp;x ULN</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>placebo</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>infliximab</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>placebo</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>infliximab</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>placebo</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>infliximab</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>placebo</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>infliximab</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Rheumatoid
  arthritis<sup>1</sup></span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>375</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1,087</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>58.1</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>58.3</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3.2%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3.9%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.8%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.9%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Crohn&#8217;s
  disease<sup>2</sup></span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>324</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1034</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>53.7</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>54.0</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.2%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.9%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.5%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Paediatric
  Crohn&#8217;s disease</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>139</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>53.0</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.4%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.5%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Ulcerative
  colitis</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>242</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>482</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>30.1</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>30.8</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.2%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.5%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.4%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.6%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Paediatric
  Ulcerative colitis</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>60</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>49.4</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6.7%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>N/A</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.7%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Ankylosing
  spondylitis</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>76</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>275</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>24.1</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>101.9</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9.5%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3.6%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Psoriatic
  arthritis</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>98</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>191</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>18.1</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39.1</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>6.8%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=80 valign=top style='width:60.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Plaque psoriasis</span></p>
  </td>
  <td width=59 valign=top style='width:44.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>281</span></p>
  </td>
  <td width=74 valign=top style='width:55.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1,175</span></p>
  </td>
  <td width=61 valign=top style='width:45.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>16.1</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>50.1</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.4%</span></p>
  </td>
  <td width=71 valign=top style='width:53.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7.7%</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0%</span></p>
  </td>
  <td width=74 valign=top style='width:55.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3.4%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=611 colspan=9 valign=top style='width:457.9pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>1</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Placebo
  patients received methotrexate while infliximab patients received both
  infliximab and methotrexate.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>2</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Placebo
  patients in the 2&nbsp;Phase III studies in Crohn&#8217;s disease, ACCENT I and
  ACCENT II, received an initial dose of 5&nbsp;mg/kg infliximab at study start
  and were on placebo in the maintenance phase. Patients who were randomised to
  the placebo maintenance group and then later crossed over to infliximab are
  included in the infliximab group in the ALT analysis. In the Phase IIIb trial
  in Crohn&#8217;s disease, SONIC, placebo patients received AZA 2.5&nbsp;mg/kg/day
  as active control in addition to placebo infliximab infusions.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>3</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Number
  of patients evaluated for ALT.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>4</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Median
  follow&#8209;up is based on patients treated.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antinuclear
antibodies (ANA)/Anti&#8209;double&#8209;stranded DNA (dsDNA) antibodies</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Approximately half of infliximab&#8209;treated
patients in clinical studies who were ANA negative at baseline developed a
positive ANA during the study compared with approximately one&nbsp;fifth of
placebo&#8209;treated patients. Anti&#8209;dsDNA antibodies were newly detected
in approximately 17% of infliximab&#8209;treated patients compared with 0% of
placebo&#8209;treated patients. At the last evaluation, 57% of infliximab&#8209;treated
patients remained anti&#8209;dsDNA positive. Reports of lupus and lupus&#8209;like
syndromes, however, remain uncommon (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Paediatric
population</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Juvenile
rheumatoid arthritis patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Remicade was studied in a clinical study </span><span
lang=EN-GB>in</span><span lang=EN-GB> 120&nbsp;patients </span><span
lang=EN-GB>(age range: 4&#8209;17&nbsp;years old) </span><span lang=EN-GB>with
active juvenile rheumatoid arthritis despite methotrexate. </span><span
lang=EN-GB>Patients received 3 or 6&nbsp;mg/kg infliximab as a 3&#8209;dose
induction regimen (weeks&nbsp;0, 2, 6 or weeks&nbsp;14, 16, 20&nbsp;respectively)
followed by maintenance therapy every 8&nbsp;weeks, in combination with methotrexate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion
reactions</span></p>

<p class=MsoNormal><span lang=EN-GB>Infusion reactions occurred in 35% of
patients with juvenile rheumatoid arthritis receiving 3&nbsp;mg/kg compared
with 17.5% of patients receiving 6&nbsp;mg/kg. In the 3&nbsp;mg/kg Remicade
group, 4 out of 60&nbsp;patients had a serious infusion reaction and
3&nbsp;patients reported a possible anaphylactic reaction (2 of which were
among the serious infusion reactions). In the 6&nbsp;mg/kg group, 2 out of 57&nbsp;patients
had a serious infusion reaction, one of whom had a possible anaphylactic
reaction (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immunogenicity</span></p>

<p class=MsoNormal><span lang=EN-GB>Antibodies to infliximab developed in 38%
of patients receiving 3&nbsp;mg/kg compared with 12% of patients receiving 6&nbsp;mg/kg.
The antibody titres were notably higher for the 3&nbsp;mg/kg compared to the 6&nbsp;mg/kg
group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections</span></p>

<p class=MsoNormal><span lang=EN-GB>Infections occurred in 68% (41/60) of
children receiving 3&nbsp;mg/kg over 52&nbsp;weeks, 65% (37/57) of children
receiving infliximab 6&nbsp;mg/kg over 38&nbsp;weeks and 47% (28/60) of
children receiving placebo over 14&nbsp;weeks (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
Crohn&#8217;s disease patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The following adverse reactions were
reported more commonly in paediatric Crohn&#8217;s disease patients in the
REACH study (see section&nbsp;5.1) than in adult Crohn&#8217;s disease
patients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing
(8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%),
and respiratory tract allergic reaction (5.8%). In addition, bone fracture
(6.8%) was reported, however, a causal association has not been established. Other
special considerations are discussed below.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion&#8209;related
reactions</span></p>

<p class=MsoNormal><span lang=EN-GB>In REACH, 17.5% of randomised patients
experienced 1 or more infusion reactions. There were no serious infusion
reactions, and 2&nbsp;subjects in REACH had non&#8209;serious anaphylactic
reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immunogenicity</span></p>

<p class=MsoNormal><span lang=EN-GB>Antibodies to infliximab were detected in 3
(2.9%) paediatric patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections</span></p>

<p class=MsoNormal><span lang=EN-GB>In the REACH study, infections were
reported in 56.3% of randomised subjects treated with infliximab. Infections
were reported more frequently for subjects who received q8&nbsp;week as opposed
to q12&nbsp;week infusions (73.6% and 38.0%, respectively), while serious
infections were reported for 3&nbsp;subjects in the q8&nbsp;week and
4&nbsp;subjects in the q12&nbsp;week maintenance treatment group. The most
commonly reported infections were upper respiratory tract infection and
pharyngitis, and the most commonly reported serious infection was abscess.
Three cases of pneumonia (1&nbsp;serious) and 2&nbsp;cases of herpes zoster
(both non&#8209;serious) were reported.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
ulcerative colitis patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the adverse reactions reported in
the paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis
(ACT&nbsp;1 and ACT&nbsp;2) studies were generally consistent. In C0168T72, the
most common adverse reactions were upper respiratory tract infection,
pharyngitis, abdominal pain, fever, and headache. The most common adverse event
was worsening of ulcerative colitis, the incidence of which was higher in
patients on the q12&nbsp;week vs. the q8&nbsp;week dosing regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion&#8209;related
reactions</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, 8 (13.3%) of 60&nbsp;treated patients
experienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8&nbsp;week
and 3 of 23 (13.0%) in the q12&nbsp;week treatment maintenance group. No
serious infusion reactions were reported. All infusion reactions were mild or
moderate in intensity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immunogenicity</span></p>

<p class=MsoNormal><span lang=EN-GB>Antibodies to infliximab were detected in
4&nbsp;(7.7%) patients through week&nbsp;54.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections</span></p>

<p class=MsoNormal><span lang=EN-GB>Infections were reported in 31 (51.7%) of
60&nbsp;treated patients in C0168T72 and 22 (36.7%) required oral or parenteral
antimicrobial treatment. The proportion of patients with infections in C0168T72
was similar to that in the paediatric Crohn&#8217;s disease study (REACH) but
higher than the proportion in the adults ulcerative colitis studies (ACT&nbsp;1
and ACT&nbsp;2). The overall incidence of infections in C0168T72 was 13/22
(59%) in the every 8&nbsp;week maintenance treatment group and 14/23 (60.9%) in
the every 12&nbsp;week maintenance treatment group. Upper respiratory tract
infection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently
reported respiratory system infections. Serious infections were reported in 12%
(7/60) of all treated patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In this study, there were more patients in
the 12 to 17&nbsp;year age group than in the 6 to 11&nbsp;year age group (45/60
[75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are
too small to make any definitive conclusions about the effect of age on safety
events, there were higher proportions of patients with serious adverse events
and discontinuation due to adverse events in the younger age group than in the older
age group. While the proportion of patients with infections was also higher in
the younger age group, for serious infections, the proportions were similar in
the two age groups. Overall proportions of adverse events and infusion
reactions were similar between the 6 to 11 and 12 to 17&nbsp;year age groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Post&#8209;marketing
experience</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Post&#8209;marketing spontaneous serious
adverse reactions with infliximab in the paediatric population have included
malignancies including hepatosplenic T&#8209;cell lymphomas, transient hepatic
enzyme abnormalities, lupus&#8209;like syndromes, and positive auto&#8209;antibodies
(see sections&nbsp;4.4 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Additional
information on special populations</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In rheumatoid
arthritis clinical studies, the incidence of serious infections was greater in
infliximab plus methotrexate&#8209;treated patients 65&nbsp;years and older
(11.3%) than in those under 65&nbsp;years of age (</span><span lang=EN-GB>4.6%).
In patients treated with methotrexate alone, the incidence of serious
infections<span style='layout-grid-mode:line'> was 5.2% </span>in patients 65&nbsp;years
and older compared to 2.7% in patients under 65 </span><span lang=EN-GB>(see
section&nbsp;4.4).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions <span
style='background:silver'>via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No case of overdose has been reported.
Single doses up to 20&nbsp;mg/kg have been administered without toxic effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: </span><a
name="_Hlk509410677"><span lang=EN-GB>Immunosuppressants</span></a><span
lang=EN-GB>, tumour necrosis factor alpha (TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB>) inhibitors, ATC
code: L04AB02.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Mechanism
of action</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab is a chimeric human&#8209;murine
monoclonal antibody that binds with high affinity to both soluble and
transmembrane forms of TNF</span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB> but not to lymphotoxin </span><span lang=EN-GB style='font-family:
Symbol'>a</span><span lang=EN-GB> (TNF<sub>&szlig;</sub>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab inhibits the functional activity
of TNF</span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB> in a wide variety of <i>in vitro </i>bioassays. Infliximab
prevented disease in transgenic mice that develop polyarthritis as a result of
constitutive expression of human TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB> and when
administered after disease onset, it allowed eroded joints to heal. <i>In vivo</i>,
infliximab rapidly forms stable complexes with human TNF</span><sub><span
lang=EN-GB style='font-family:Symbol'>a</span></sub><span lang=EN-GB>, a
process that parallels the loss of TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB> bioactivity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Elevated concentrations of TNF</span><sub><span
lang=EN-GB style='font-family:Symbol'>a</span></sub><span lang=EN-GB> have been
found in the joints of rheumatoid arthritis patients and correlate with
elevated disease activity. In rheumatoid arthritis, treatment with infliximab
reduced infiltration of inflammatory cells into inflamed areas of the joint as
well as expression of molecules mediating cellular adhesion, chemoattraction
and tissue degradation. After infliximab treatment, patients exhibited
decreased levels of serum interleukin&nbsp;6 (IL&#8209;6) and C&#8209;reactive
protein (CRP)<b>, </b>and increased haemoglobin levels in rheumatoid arthritis
patients with reduced haemoglobin levels, compared with baseline. Peripheral
blood lymphocytes further showed no significant decrease in number or in
proliferative responses to <i>in vitro</i> mitogenic stimulation when compared
with untreated patients&#8217; cells. In psoriasis patients, treatment with
infliximab resulted in decreases in epidermal inflammation and normalisation of
keratinocyte differentiation in psoriatic plaques. In psoriatic arthritis,
short term treatment with Remicade reduced the number of T&#8209;cells and
blood vessels in the synovium and psoriatic skin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Histological evaluation of colonic
biopsies, obtained before and 4&nbsp;weeks after administration of infliximab,
revealed a substantial reduction in detectable TNF</span><sub><span lang=EN-GB
style='font-family:Symbol'>a</span></sub><span lang=EN-GB>. Infliximab
treatment of Crohn&#8217;s disease patients was also associated with a substantial
reduction of the commonly elevated serum inflammatory marker, CRP. Total
peripheral white blood cell counts were minimally affected in infliximab&#8209;treated
patients, although changes in lymphocytes, monocytes and neutrophils reflected
shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from
infliximab&#8209;treated patients showed undiminished proliferative
responsiveness to stimuli compared with untreated patients, and no substantial
changes in cytokine production by stimulated PBMC were observed following
treatment with infliximab. Analysis of lamina propria mononuclear cells
obtained by biopsy of the intestinal mucosa showed that infliximab treatment
caused a reduction in the number of cells capable of expressing TNF</span><sub><span
lang=EN-GB style='font-family:Symbol'>a</span></sub><span lang=EN-GB> and
interferon</span><span lang=EN-GB style='font-family:Symbol'>g</span><span
lang=EN-GB>. Additional histological studies provided evidence that treatment
with infliximab reduces the infiltration of inflammatory cells into affected
areas of the intestine and the presence of inflammation markers at these sites.
Endoscopic studies of intestinal mucosa have shown evidence of mucosal healing
in infliximab&#8209;treated patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
rheumatoid arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of infliximab was assessed in
two multicentre, randomised, double&#8209;blind,<b> </b>pivotal clinical
studies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of
folic acid, oral corticosteroids (&#8804;&nbsp;10&nbsp;mg/day) and/or non&#8209;steroidal
antiinflammatory drugs (NSAIDs) was permitted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoints were the reduction of
signs and symptoms as assessed by the American College of Rheumatology criteria
(ACR20 for ATTRACT, landmark ACR&#8209;N for ASPIRE), the prevention of
structural joint damage, and the improvement in physical function. A reduction
in signs and symptoms was defined to be at least a 20% improvement (ACR20) in
both tender and swollen joint counts, and in 3 of the following 5&nbsp;criteria:
(1) evaluator&#8217;s global assessment, (2) patient&#8217;s global assessment,
(3) functional/disability measure, (4) visual analogue pain scale and (5)
erythrocyte sedimentation rate or C&#8209;reactive protein. ACR&#8209;N uses
the same criteria as the ACR20, calculated by taking the lowest percent
improvement in swollen joint count, tender joint count, and the median of the
remaining 5&nbsp;components of the ACR response. Structural joint damage (erosions
and joint space narrowing) in both hands and feet was measured by the change
from baseline in the total van der Heijde&#8209;modified Sharp score (0&#8209;440).
The Health Assessment Questionnaire (HAQ; scale&nbsp;0&#8209;3) was used to
measure patients&#8217; average change from baseline scores over time, in
physical function.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ATTRACT study evaluated responses at
30, 54 and 102&nbsp;weeks in a placebo&#8209;controlled study of 428&nbsp;patients
with active rheumatoid arthritis despite treatment with methotrexate.
Approximately 50% of patients were in functional Class III. Patients received
placebo, 3&nbsp;mg/kg or 10&nbsp;mg/kg infliximab at weeks&nbsp;0, 2 and 6, and
then every 4 or 8&nbsp;weeks thereafter. All patients were on stable
methotrexate doses (median 15&nbsp;mg/wk) for 6&nbsp;months prior to enrolment
and were to remain on stable doses throughout the study.</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from week&nbsp;54 (ACR20, total van
der Heijde&#8209;modified Sharp score and HAQ) are shown in Table&nbsp;3.
Higher degrees of clinical response (ACR50 and ACR70) were observed in all
infliximab groups at 30 and 54&nbsp;weeks compared with methotrexate alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A reduction in the rate of the progression
of structural joint damage (erosions and joint space narrowing) was observed in
all infliximab groups at 54&nbsp;weeks (Table&nbsp;3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The effects observed at 54&nbsp;weeks were
maintained through 102&nbsp;weeks. Due to a number of treatment withdrawals,
the magnitude of the effect difference between infliximab and the methotrexate
alone group cannot be defined.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=615 colspan=7 style='width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Effects on ACR20,
  Structural Joint Damage and Physical Function at week&nbsp;54, ATTRACT</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=273 colspan=2 style='width:204.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=343 colspan=5 style='width:257.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>infliximab</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 valign=bottom style='width:153.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=68 valign=bottom style='width:51.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Control</span><sup><span
  lang=EN-GB>a</span></sup></p>
  </td>
  <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>3&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>q&nbsp;8&nbsp;wks</span></p>
  </td>
  <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>3&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>q&nbsp;4&nbsp;wks</span></p>
  </td>
  <td width=68 valign=bottom style='width:51.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>q&nbsp;8&nbsp;wks</span></p>
  </td>
  <td width=67 valign=bottom style='width:50.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>q&nbsp;4&nbsp;wks</span></p>
  </td>
  <td width=72 valign=bottom style='width:53.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>All infliximab</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with
  ACR20 response/</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients
  evaluated (%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>15/88</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(17%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>36/86</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(42%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>41/86</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(48%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>51/87</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(59%)</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>48/81</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(59%)</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>176/340</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(52%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=615 colspan=7 style='width:461.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Total score</span><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:10.0pt'> (van der
  Heijde&#8209;modified Sharp score)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Change from
  baseline (Mean &plusmn; SD</span><sup><span lang=EN-GB>c</span></sup><span
  lang=EN-GB style='font-size:10.0pt'>)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7.0&nbsp;&plusmn;&nbsp;10.3</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.3&nbsp;&plusmn;&nbsp;6.0</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.6&nbsp;&plusmn;&nbsp;8.5</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.2&nbsp;&plusmn;&nbsp;3.6</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&#8209;0.7&nbsp;&plusmn;&nbsp;3.8</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.6&nbsp;&plusmn;&nbsp;5.9</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Median</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(Interquartile
  range)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.0</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.5,9.7)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(&#8209;1.5,3.0)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.1</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(&#8209;2.5,3.0)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(&#8209;1.5,2.0)</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>&#8209;0.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(&#8209;3.0,1.5)</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.0</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(&#8209;1.8,2.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Patients with no
  deterioration/patients evaluated (%)</span><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13/64</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(20%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>34/71</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(48%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>35/71</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(49%)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>37/77</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(48%)</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>44/66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(67%)</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>150/285</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>(53%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=615 colspan=7 style='width:461.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>HAQ change from
  baseline over time<sup>e</sup> (patients evaluated)</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>87</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>86</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>85</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>87</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>81</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>339</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=205 style='width:153.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Mean &plusmn; SD</span><sup><span
  lang=EN-GB>c</span></sup></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.2&nbsp;&plusmn;&nbsp;0.3</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.4&nbsp;&plusmn;&nbsp;0.3</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.5&nbsp;&plusmn;&nbsp;0.4</span></p>
  </td>
  <td width=68 style='width:51.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.5&nbsp;&plusmn;&nbsp;0.5</span></p>
  </td>
  <td width=67 style='width:50.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.4&nbsp;&plusmn;&nbsp;0.4</span></p>
  </td>
  <td width=72 style='width:53.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;layout-grid-mode:line'>0.4&nbsp;&plusmn;&nbsp;0.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=615 colspan=7 style='width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB style='layout-grid-mode:line'>a</span></sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>&nbsp;&nbsp;&nbsp;&nbsp; control&nbsp;=&nbsp;</span><span
  lang=EN-GB style='font-size:9.0pt'>All patients had active RA despite
  treatment with stable methotrexate doses for 6&nbsp;months prior to enrolment
  and were to remain on stable doses throughout the study. Concurrent use of
  stable doses of oral corticosteroids (&#8804;&nbsp;10&nbsp;mg/day) and/or
  NSAIDs was permitted, and folate supplementation was given.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB style='layout-grid-mode:line'>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>&nbsp;&nbsp;&nbsp;&nbsp; all
  infliximab doses given in combination with methotrexate and</span><span
  lang=EN-GB style='font-size:9.0pt'> folate with some on corticosteroids
  and/or NSAIDs</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; <span
  style='layout-grid-mode:line'>p&nbsp;&lt;&nbsp;0.001, for each infliximab
  treatment group vs. control</span></span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; greater
  values indicate more joint damage.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; HAQ&nbsp;=&nbsp;Health
  Assessment Questionnaire; greater values indicate less disability.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ASPIRE study evaluated responses at
54&nbsp;weeks in 1,004&nbsp;methotrexate naive patients with early (<span
style='layout-grid-mode:line'>&#8804;&nbsp;3&nbsp;years disease duration, median
0.6&nbsp;years) </span>active rheumatoid arthritis (median swollen and tender
joint count of 19 and 31, respectively). All patients received methotrexate
(optimised to 20&nbsp;mg/wk by week&nbsp;8) and either placebo, 3&nbsp;mg/kg or
6&nbsp;mg/kg infliximab at weeks&nbsp;0, 2, and 6 and every 8&nbsp;weeks
thereafter. Results from week&nbsp;54 are shown in Table&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After 54&nbsp;weeks of treatment, both
doses of infliximab + methotrexate resulted in statistically significantly
greater improvement in signs and symptoms compared to methotrexate alone as
measured by the proportion of patients achieving ACR20, 50 and
70&nbsp;responses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In ASPIRE, more than 90% of patients had at
least two evaluable X&#8209;rays. Reduction in the rate of progression of
structural damage was observed at weeks&nbsp;30 and 54 in the infliximab +
methotrexate groups compared to methotrexate alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=603 colspan=5 valign=bottom style='width:452.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;4</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Effects on ACRn, Structural Joint Damage and
  Physical Function at week&nbsp;54, ASPIRE</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=339 colspan=2 valign=bottom style='width:254.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 colspan=3 valign=bottom style='width:197.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab +&nbsp;MTX</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo +&nbsp;MTX</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3&nbsp;mg/kg</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6&nbsp;mg/kg</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Combined</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Subjects randomised</span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>282</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>359</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>363</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>722</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Percentage ACR improvement</span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Mean &plusmn; SD<sup>a</sup></span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>24.8&nbsp;&plusmn;&nbsp;59.7</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>37.3&nbsp;&plusmn;&nbsp;52.8</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>42.0&nbsp;&plusmn;&nbsp;47.3</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39.6&nbsp;&plusmn;&nbsp;50.1</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Change from baseline in total van der
  Heijde&#8209;modified Sharp score<sup>b</sup></span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Mean &plusmn; SD<sup>a</sup></span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3.70&nbsp;&plusmn;&nbsp;9.61</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.42&nbsp;&plusmn;&nbsp;5.82</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.51&nbsp;&plusmn;&nbsp;5.55</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.46&nbsp;&plusmn;&nbsp;5.68</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Median</span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.43</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.00</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.00</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Improvement from baseline in HAQ averaged
  over time from week&nbsp;30 to week&nbsp;54<sup>c</sup></span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=bottom style='width:172.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>Mean &plusmn; SD<sup>d</sup></span></p>
  </td>
  <td width=109 valign=bottom style='width:81.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.68&nbsp;&plusmn;&nbsp;0.63</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.80&nbsp;&plusmn;&nbsp;0.65</span></p>
  </td>
  <td width=85 valign=bottom style='width:63.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.88&nbsp;&plusmn;&nbsp;0.65</span></p>
  </td>
  <td width=94 valign=bottom style='width:70.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.84&nbsp;&plusmn;&nbsp;0.65</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=603 colspan=5 valign=bottom style='width:452.25pt;border:none;
  padding:0in 1.4pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; <span
  style='layout-grid-mode:line'>p&nbsp;&lt;&nbsp;0.001, for each infliximab
  treatment group vs. control.</span></span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; greater
  values indicate more joint damage.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; HAQ&nbsp;=&nbsp;Health
  Assessment Questionnaire; greater values indicate less disability.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; p&nbsp;=&nbsp;0.030
  and &lt;&nbsp;0.001 for the 3&nbsp;mg/kg and 6&nbsp;mg/kg treatment groups
  respectively vs. placebo + MTX.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Data to support
dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START
study. START was a randomised, multicenter, double&#8209;blind, 3&#8209;arm,
parallel&#8209;group safety study. In one of the study arms (group 2, n&nbsp;=&nbsp;329),
patients with an inadequate response were allowed to dose titrate with 1.5&nbsp;mg/kg
increments from 3 up to 9&nbsp;mg/kg. <a name="OLE_LINK2">The majority (67%) of
these patients did not require any dose titration. </a>Of the patients who
required a dose titration, 80% achieved clinical response and the majority
(64%) of these required only one adjustment of 1.5&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Adult Crohn&#8217;s disease</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Induction
treatment in moderately to severely active Crohn&#8217;s disease</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of a single dose treatment
with infliximab was assessed in 108&nbsp;patients with active Crohn&#8217;s
disease (Crohn&#8217;s Disease Activity Index (CDAI)&nbsp;&#8805;&nbsp;220&nbsp;&#8804;&nbsp;400)
in a randomised, double&#8209;blinded, placebo&#8209;controlled, dose&#8209;response
study. Of these 108&nbsp;patients, 27 were treated with the recommended dosage
of infliximab 5&nbsp;mg/kg. All patients had experienced an inadequate response
to prior conventional therapies. Concurrent use of stable doses of conventional
therapies was permitted, and 92% of patients continued to receive these
therapies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint was the proportion of
patients who experienced a clinical response, defined as a decrease in CDAI by &#8805;&nbsp;70&nbsp;points
from baseline at the 4&#8209;week evaluation and without an increase in the use
of medicinal products or surgery for Crohn&#8217;s disease. Patients who
responded at week&nbsp;4 were followed to week&nbsp;12. Secondary endpoints
included the proportion of patients in clinical remission at week&nbsp;4
(CDAI&nbsp;&lt;&nbsp;150) and clinical response over time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At week&nbsp;4, following administration of
a single dose, 22/27&nbsp;(81%) of infliximab&#8209;treated patients receiving
a 5&nbsp;mg/kg dose achieved a clinical response vs. 4/25&nbsp;(16%) of the
placebo&#8209;treated patients (p&nbsp;&lt;&nbsp;0.001). Also at week&nbsp;4,
13/27&nbsp;(48%) of infliximab&#8209;treated patients achieved a clinical
remission (CDAI&nbsp;&lt;&nbsp;150) vs. 1/25&nbsp;(4%) of placebo&#8209;treated
patients. A response was observed within 2&nbsp;weeks, with a maximum response
at 4&nbsp;weeks. At the last observation at 12&nbsp;weeks, 13/27&nbsp;(48%) of
infliximab&#8209;treated patients were still responding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Maintenance
treatment in moderately to severely active Crohn&#8217;s disease in adults</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of repeated infusions with
infliximab was studied in a 1&#8209;year clinical study (ACCENT I).</span></p>

<p class=MsoNormal><span lang=EN-GB>A total of 573&nbsp;patients with
moderately to severely active Crohn&#8217;s disease (CDAI&nbsp;&#8805;&nbsp;220&nbsp;&#8804;&nbsp;400)
received a single infusion of 5&nbsp;mg/kg at week&nbsp;0. 178 of the
580&nbsp;enrolled patients (30.7%) were defined as having severe disease (CDAI
score &gt;&nbsp;300 and concomitant corticosteroid and/or immunosuppressants)
corresponding to the population defined in the indication (see section&nbsp;4.1).
At week&nbsp;2, all patients were assessed for clinical response and randomised
to one of 3&nbsp;treatment groups; a placebo maintenance group, 5&nbsp;mg/kg
maintenance group and 10&nbsp;mg/kg maintenance group. All 3&nbsp;groups
received repeated infusions at week&nbsp;2, 6 and every 8&nbsp;weeks
thereafter.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Of the 573&nbsp;patients randomised, 335
(58%) achieved clinical response by week&nbsp;2. These patients were classified
as week&#8209;2 responders and were included in the primary analysis (see Table&nbsp;5).
Among patients classified as non&#8209;responders at week&nbsp;2, 32% (26/81)
in the placebo maintenance group and 42% (68/163) in the infliximab group
achieved clinical response by week&nbsp;6. There was no difference between
groups in the number of late responders thereafter.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The co&#8209;primary endpoints were the
proportion of patients in clinical remission (CDAI&nbsp;&lt;&nbsp;150) at week&nbsp;30
and time to loss of response through week&nbsp;54. Corticosteroid tapering was
permitted after week&nbsp;6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;5</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Effects on response and remission rate, data from
  ACCENT I (week&#8209;2 responders)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=435 colspan=3 valign=top style='width:325.95pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>ACCENT I (week&#8209;2 responders)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>% of Patients</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo Maintenance</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n&nbsp;=&nbsp;110)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab Maintenance</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n&nbsp;=&nbsp;113)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(p value)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Maintenance</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n&nbsp;=&nbsp;112)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(p value)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Median time to loss of response through week&nbsp;54</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>19&nbsp;weeks</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>38&nbsp;weeks</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.002)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;54&nbsp;weeks</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;30</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical Response<sup>a</sup></span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27.3</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>51.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>59.1</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical Remission</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>20.9</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>38.9</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.003)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Steroid&#8209;Free Remission</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>10.7
  (6/56)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>31.0
  (18/58)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.008)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36.8
  (21/57)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;54</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical Response<sup>a</sup></span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15.5</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>38.1</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47.7</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical Remission</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>13.6</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>28.3</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.007)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>38.4</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(&lt;&nbsp;0.001)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Sustained Steroid&#8209;Free Remission<sup>b</sup></span></p>
  </td>
  <td width=145 style='width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5.7
  (3/53)</span></p>
  </td>
  <td width=145 valign=top style='width:108.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>17.9
  (10/56)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.075)</span></p>
  </td>
  <td width=145 style='width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>28.6
  (16/56)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.002)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Reduction
  in CDAI &#8805;&nbsp;25% and &#8805;&nbsp;70&nbsp;points.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; CDAI&nbsp;&lt;&nbsp;150
  at both week&nbsp;30 and 54 and not receiving corticosteroids in the
  3&nbsp;months prior to week&nbsp;54 among patients who were receiving
  corticosteroids at baseline.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Beginning at
week&nbsp;14, patients who had responded to treatment, but subsequently lost
their clinical benefit, were allowed to cross over to a dose of infliximab 5&nbsp;mg/kg
higher than the dose to which they were originally randomised. Eighty&nbsp;nine
percent (50/56) of patients who lost clinical response on infliximab 5&nbsp;mg/kg
maintenance therapy after week&nbsp;14 responded to treatment with infliximab
10&nbsp;mg/kg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Improvements in quality of life measures, a
reduction in disease&#8209;related hospitalisations and corticosteroid use were
seen in the infliximab maintenance groups compared with the placebo maintenance
group at weeks&nbsp;30 and 54.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab with or without AZA was assessed
in a randomised, double&#8209;blind, active comparator study (SONIC) of 508&nbsp;adult
patients with moderate to severe Crohn&#8217;s disease (CDAI&nbsp;&#8805;&nbsp;220&nbsp;&#8804;&nbsp;450)
who were naive to biologics and immunosuppressants </span><span lang=EN-GB>and
had a median disease duration of 2.3&nbsp;years. </span><span lang=EN-GB>At
baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of
patients were receiving budesonide, and 54.3% of patients were receiving 5&#8209;ASA
compounds. Patients were randomised to receive AZA monotherapy, infliximab
monotherapy, or infliximab plus AZA combination therapy. Infliximab was
administered at a dose of 5&nbsp;mg/kg at weeks&nbsp;0, 2, 6, and then every 8&nbsp;weeks.
AZA was given at a dose of 2.5&nbsp;mg/kg daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint of the study was
corticosteroid&#8209;free clinical remission at week&nbsp;26, defined as
patients in clinical remission (CDAI of &lt;&nbsp;150) who, for at least
3&nbsp;weeks, had not taken oral systemic corticosteroids (prednisone or
equivalent) or budesonide at a dose &gt;&nbsp;6&nbsp;mg/day. For results see
Table&nbsp;6. The proportions of patients with mucosal healing at week&nbsp;26&nbsp;were
significantly greater in the infliximab plus AZA combination (43.9%,
p&nbsp;&lt;&nbsp;0.001) and infliximab monotherapy groups (30.1%, p&nbsp;=&nbsp;0.023)
compared to the AZA monotherapy group (16.5%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=bottom style='width:453.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;6</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Percent of patients achieving corticosteroid&#8209;free
  clinical remission at week&nbsp;26, SONIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=185 valign=bottom style='width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=140 valign=bottom style='width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>AZA</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Monotherapy</span></p>
  </td>
  <td width=140 valign=bottom style='width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Monotherapy</span></p>
  </td>
  <td width=140 valign=bottom style='width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab + AZA</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Combination Therapy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=bottom style='width:453.55pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;26</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=185 valign=top style='width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal><span lang=EN-GB>All randomised patients</span></p>
  </td>
  <td width=140 valign=top style='width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>30.0%
  (51/170)</span></p>
  </td>
  <td width=140 valign=top style='width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>44.4%
  (75/169)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(p&nbsp;=&nbsp;0.006)<sup>*</sup></span></p>
  </td>
  <td width=140 valign=top style='width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>56.8%
  (96/169)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(p&nbsp;&lt;&nbsp;0.001)<sup>*</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:453.55pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB style='font-size:9.0pt'>*&nbsp;&nbsp;&nbsp; P&#8209;values
  represent each infliximab treatment group vs. AZA monotherapy.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Similar trends in the achievement of
corticosteroid&#8209;free clinical remission were observed at week&nbsp;50. </span><span
lang=EN-GB>Furthermore, improved quality of life as measured by IBDQ was
observed with infliximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Induction
treatment in fistulising active Crohn&#8217;s disease</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy was assessed in a randomised,
double&#8209;blinded, placebo&#8209;controlled study in 94&nbsp;patients with
fistulising Crohn&#8217;s disease who had fistulae that were of at least
3&nbsp;months&#8217; duration. Thirty&nbsp;one of these patients were treated
with infliximab 5&nbsp;mg/kg. Approximately 93% of the patients had previously
received antibiotic or immunosuppressive therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concurrent use of stable doses of
conventional therapies was permitted, and 83% of patients continued to receive
at least one of these therapies. Patients received three doses of either
placebo or infliximab at weeks&nbsp;0, 2 and 6. Patients were followed up to 26&nbsp;weeks.
The primary endpoint was the proportion of patients who experienced a clinical
response, defined as&nbsp;&#8805;&nbsp;50% reduction from baseline in the
number of fistulae draining upon gentle compression on at least two consecutive
visits (4&nbsp;weeks apart), without an increase in the use of medicinal
products or surgery for Crohn&#8217;s disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sixty&nbsp;eight percent (21/31) of
infliximab&#8209;treated patients receiving a 5&nbsp;mg/kg dose regimen
achieved a clinical response vs. 26% (8/31) placebo&#8209;treated patients (p&nbsp;=&nbsp;0.002).
The median time to onset of response in the infliximab&#8209;treated group was
2&nbsp;weeks. The median duration of response was 12&nbsp;weeks. Additionally,
closure of all fistulae was achieved in 55% of infliximab&#8209;treated
patients compared with 13% of placebo&#8209;treated patients (p&nbsp;=&nbsp;0.001).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Maintenance
treatment in fistulising active Crohn&#8217;s disease</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of repeated infusions with
infliximab in patients with fistulising Crohn&#8217;s disease was studied in a
1&#8209;year clinical study (ACCENT II). A total of 306&nbsp;patients received
3&nbsp;doses of infliximab 5&nbsp;mg/kg at week&nbsp;0, 2 and 6. At baseline,
87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had
rectovaginal fistulae. The median CDAI score was 180. At week&nbsp;14,
282&nbsp;patients were assessed for clinical response and randomised to receive
either placebo or 5&nbsp;mg/kg infliximab every 8&nbsp;weeks through week&nbsp;46.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Week&#8209;14&nbsp;responders (195/282)
were analysed for the primary endpoint, which was time from randomisation to
loss of response (see Table&nbsp;7). Corticosteroid tapering was permitted
after week&nbsp;6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;7</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Effects on response rate, data from ACCENT II
  (week&#8209;14&nbsp;responders)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=251 valign=top style='width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=354 colspan=3 valign=top style='width:265.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>ACCENT II
  (week&#8209;14&nbsp;responders)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=251 valign=top style='width:188.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Maintenance</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n&nbsp;=&nbsp;99)</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Maintenance</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(5&nbsp;mg/kg)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(n&nbsp;=&nbsp;96)</span></p>
  </td>
  <td width=118 valign=top style='width:88.45pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=251 valign=top style='width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Median time to loss of response<sup> </sup>through
  week&nbsp;54</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14&nbsp;weeks</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;40&nbsp;weeks</span></p>
  </td>
  <td width=118 valign=top style='width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;&nbsp;0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;54</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=251 valign=top style='width:188.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Fistula Response (%)<sup>a</sup></span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>23.5</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>46.2</span></p>
  </td>
  <td width=118 valign=top style='width:88.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=251 valign=top style='width:188.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Complete fistula response (%)<sup>b</sup></span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>19.4</span></p>
  </td>
  <td width=118 valign=top style='width:88.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36.3</span></p>
  </td>
  <td width=118 valign=top style='width:88.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.009</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=4 valign=top style='width:6.3in;border:none;border-top:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; A
  &#8805;&nbsp;50% reduction from baseline in the number of draining fistulas
  over a period of &#8805;&nbsp;4&nbsp;weeks.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Absence
  of any draining fistulas.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Beginning at week&nbsp;22, patients who
initially responded to treatment and subsequently lost their response were
eligible to cross over to active re&#8209;treatment every 8&nbsp;weeks at a
dose of infliximab 5&nbsp;mg/kg higher than the dose to which they were
originally randomised. Among patients in the infliximab 5&nbsp;mg/kg group who
crossed over because of loss of fistula response after week&nbsp;22, 57%
(12/21) responded to re&#8209;treatment with infliximab 10&nbsp;mg/kg every 8&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There was no significant difference between
placebo and infliximab for the proportion of patients with sustained closure of
all fistulas through week&nbsp;54, for symptoms such as proctalgia, abscesses
and urinary tract infection or for number of newly developed fistulas during
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Maintenance therapy with infliximab every 8&nbsp;weeks
significantly reduced disease&#8209;related hospitalisations and surgeries
compared with placebo. Furthermore, a reduction in corticosteroid use and
improvements in quality of life were observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult ulcerative
colitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Remicade were
assessed in two (ACT&nbsp;1 and ACT&nbsp;2) randomised, double&#8209;blind,
placebo&#8209;controlled clinical studies in adult patients with moderately to
severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore &#8805;&nbsp;2)
with an inadequate response to conventional therapies [</span><span lang=EN-GB>oral
corticosteroids, aminosalicylates and/or immunomodulators (6&#8209;MP, AZA)]. </span><span
lang=EN-GB>Concomitant stable doses of oral aminosalicylates, corticosteroids,
and/or immunomodulatory agents were permitted. In both studies, patients were
randomised to receive either placebo, 5&nbsp;mg/kg Remicade, or 10&nbsp;mg/kg
Remicade at weeks&nbsp;0, 2, 6, 14 and 22, and in ACT&nbsp;1 at weeks&nbsp;30,
38 and 46. Corticosteroid taper was permitted after week&nbsp;8.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=6 valign=bottom style='width:454.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;8</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Effects on clinical response, clinical remission
  and mucosal healing at weeks&nbsp;8 and&nbsp;30.</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Combined data from ACT&nbsp;1 &amp; 2</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=298 colspan=2 valign=bottom style='width:223.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=308 colspan=4 valign=bottom style='width:230.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5&nbsp;mg/kg</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10&nbsp;mg/kg</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Combined</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Subjects randomised</span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>244</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>242</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>242</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>484</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=6 valign=bottom style='width:454.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Percentage
  of subjects in clinical response and in sustained clinical response</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical response at week&nbsp;8<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>33.2%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>66.9%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>65.3%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>66.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical response at week&nbsp;30<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27.9%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>49.6%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>55.4%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52.5%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Sustained response</span></p>
  <p class=MsoNormal><span lang=EN-GB>(clinical response at both</span></p>
  <p class=MsoNormal><span lang=EN-GB>week&nbsp;8 and week&nbsp;30)<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>19.3%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>45.0%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>49.6%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47.3%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=6 valign=bottom style='width:454.25pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Percentage
  of subjects in clinical remission and sustained remission</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical remission at week&nbsp;8<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>10.2%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36.4%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>29.8%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>33.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Clinical remission at week&nbsp;30<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>13.1%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>29.8%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36.4%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>33.1%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Sustained remission</span></p>
  <p class=MsoNormal><span lang=EN-GB>(in remission at both</span></p>
  <p class=MsoNormal><span lang=EN-GB>week&nbsp;8 and week&nbsp;30)<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5.3%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>19.0%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>24.4%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>21.7%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=6 valign=bottom style='width:454.25pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Percentage
  of subjects with mucosal healing</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Mucosal healing at week&nbsp;8<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>32.4%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61.2%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>60.3%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>60.7%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=195 valign=bottom style='width:146.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Mucosal healing at week&nbsp;30<sup>a</sup></span></p>
  </td>
  <td width=103 colspan=2 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27.5%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>48.3%</span></p>
  </td>
  <td width=103 valign=bottom style='width:77.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52.9%</span></p>
  </td>
  <td width=100 valign=bottom style='width:75.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>50.6%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=606 colspan=6 valign=top style='width:454.25pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; <span
  style='layout-grid-mode:line'>p&nbsp;&lt;&nbsp;0.001, for each infliximab
  treatment group vs. placebo.</span></span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=195 style='border:none'></td>
  <td width=103 style='border:none'></td>
  <td width=0 style='border:none'></td>
  <td width=103 style='border:none'></td>
  <td width=103 style='border:none'></td>
  <td width=100 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of Remicade through week&nbsp;54
was assessed in the ACT&nbsp;1 study.</span></p>

<p class=MsoNormal><span lang=EN-GB>At&nbsp;54&nbsp;weeks, 44.9% of patients in
the combined infliximab treatment group were in clinical response compared to
19.8% in the placebo treatment group (p&nbsp;&lt;&nbsp;0.001). Clinical
remission and mucosal healing occurred in a greater proportion of patients in
the combined infliximab treatment group compared to the placebo treatment group
at week&nbsp;54 (34.6% vs. 16.5%, p&nbsp;&lt;&nbsp;0.001 and 46.1% vs. 18.2%,
p&nbsp;&lt;&nbsp;0.001, respectively). The proportions of patients in sustained
response and sustained remission at week&nbsp;54 were greater in the combined
infliximab treatment group than in the placebo treatment group (37.9% vs.
14.0%, p&nbsp;&lt;&nbsp;0.001; and 20.2% vs. 6.6%, p&nbsp;&lt;&nbsp;0.001,
respectively).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A greater proportion of patients in the
combined infliximab treatment group were able to discontinue corticosteroids
while remaining in clinical remission compared to the placebo treatment group
at both week&nbsp;30 (22.3% vs. 7.2%, p&nbsp;&lt;&nbsp;0.001, pooled ACT&nbsp;1
&amp; ACT&nbsp;2 data) and week&nbsp;54 (21.0% vs. 8.9%, p&nbsp;=&nbsp;0.022,
ACT1 data).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The pooled data
analysis from the ACT&nbsp;1 and ACT&nbsp;2 studies and their extensions,
analysed from baseline through 54&nbsp;weeks, demonstrated a reduction of
ulcerative colitis&#8209;related hospitalisations and surgical procedures with
infliximab treatment. The number of ulcerative colitis&#8209;related
hospitalisations was significantly lower in the 5 and 10&nbsp;mg/kg infliximab
treatment groups than in the placebo group (mean number of hospitalisations per
100&nbsp;subject&#8209;years: 21 and 19 vs. 40 in the placebo group; p&nbsp;=&nbsp;0.019
and p&nbsp;=&nbsp;0.007, respectively). The number of ulcerative colitis&#8209;related
surgical procedures was also lower in the 5 and 10&nbsp;mg/kg infliximab
treatment groups than in the placebo group (mean number of surgical procedures
per 100&nbsp;subject&#8209;years: 22 and 19 vs. 34<i>; </i>p&nbsp;=&nbsp;0.145
and p&nbsp;=&nbsp;0.022, respectively).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The proportion
of subjects who underwent colectomy at any time within 54&nbsp;weeks following
the first infusion of study agent were collected and pooled from the ACT&nbsp;1
and ACT&nbsp;2 studies and their extensions. Fewer subjects underwent colectomy
in the 5&nbsp;mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the
10&nbsp;mg/kg infliximab group (18/242 or 7.4% [p&nbsp;=&nbsp;0.011]) than in
the placebo group (36/244; 14.8%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The reduction in incidence of colectomy was
also examined in another randomised, double&#8209;blind study (C0168Y06) in
hospitalised patients </span><span lang=EN-GB>(n&nbsp;=&nbsp;45) </span><span
lang=EN-GB>with moderately to severely active ulcerative colitis who failed to
respond to intravenous corticosteroids and who were therefore at higher risk
for colectomy. Significantly fewer colectomies occurred within 3&nbsp;months of
study infusion in patients who received a single dose of 5&nbsp;mg/kg
infliximab compared to patients who received placebo (29.2% vs. 66.7%
respectively, p&nbsp;=&nbsp;0.017).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In ACT&nbsp;1 and ACT&nbsp;2, infliximab
improved quality of life, confirmed by statistically significant improvement in
both a disease specific measure, IBDQ, and by improvement in the generic 36&#8209;item
short form survey SF&#8209;36.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
ankylosing spondylitis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy and safety of infliximab were
assessed in two multicenter, double&#8209;blind, placebo&#8209;controlled
studies in patients with active ankylosing spondylitis (Bath Ankylosing
Spondylitis Disease Activity Index [BASDAI] score &#8805;&nbsp;4 and spinal
pain &#8805;&nbsp;4 on a scale of 1&#8209;10).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the first study (P01522), which had a
3&nbsp;month double&#8209;blind phase, 70&nbsp;patients received either 5&nbsp;mg/kg
infliximab or placebo at weeks&nbsp;0, 2, 6 (35&nbsp;patients in each group).
At week&nbsp;12, placebo patients were switched to infliximab 5&nbsp;mg/kg
every 6&nbsp;weeks up to week&nbsp;54. After the first year of the study,
53&nbsp;patients continued into an open&#8209;label extension to week&nbsp;102.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the second clinical study (ASSERT), 279&nbsp;patients
were randomised to receive either placebo (Group&nbsp;1, n&nbsp;=&nbsp;78) or 5&nbsp;mg/kg
infliximab (Group&nbsp;2, n&nbsp;=&nbsp;201) at 0, 2 and 6&nbsp;weeks and every
6&nbsp;weeks to week&nbsp;24. Thereafter, all subjects continued on infliximab
every 6&nbsp;weeks to week&nbsp;96. Group&nbsp;1 received 5&nbsp;mg/kg
infliximab. In group&nbsp;2, starting with the week&nbsp;36 infusion, patients
who had a BASDAI &#8805;&nbsp;3 at 2&nbsp;consecutive visits, received 7.5&nbsp;mg/kg
infliximab every 6&nbsp;weeks thereafter through week&nbsp;96.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In ASSERT, improvement in signs and
symptoms was observed as early as week&nbsp;2. At week&nbsp;24, the number of
ASAS&nbsp;20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%)
in the 5&nbsp;mg/kg infliximab group (p&nbsp;&lt;&nbsp;0.001). There were 95&nbsp;subjects
from group&nbsp;2 who continued on 5&nbsp;mg/kg every 6&nbsp;weeks. At
102&nbsp;weeks there were 80&nbsp;subjects still on infliximab treatment and among
those, 71 (89%) were ASAS&nbsp;20 responders.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In P01522, improvement in signs and
symptoms was also observed as early as week&nbsp;2. At week&nbsp;12, the number
of BASDAI&nbsp;50 responders were 3/35 (9%) in the placebo group, and 20/35
(57%) in the 5&nbsp;mg/kg group (p&nbsp;&lt;&nbsp;0.01). There were
53&nbsp;subjects who continued on 5&nbsp;mg/kg every 6&nbsp;weeks. At
102&nbsp;weeks there were 49&nbsp;subjects still on infliximab treatment and
among those, 30 (61%) were BASDAI&nbsp;50 responders.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In both studies, physical function and
quality of life as measured by the BASFI and the physical component score of
the SF&#8209;36 were also improved significantly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
psoriatic arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy and safety were assessed in two
multicenter, double&#8209;blind, placebo&#8209;controlled studies in patients
with active psoriatic arthritis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the first clinical study (IMPACT),
efficacy and safety of infliximab were studied in 104&nbsp;patients with active
polyarticular psoriatic arthritis. During the 16&#8209;week double&#8209;blind
phase, patients received either 5&nbsp;mg/kg infliximab or placebo at weeks&nbsp;0,
2, 6, and 14 (52&nbsp;patients in each group). Starting at week&nbsp;16,
placebo patients were switched to infliximab and all patients subsequently
received 5&nbsp;mg/kg infliximab every 8&nbsp;weeks up to week&nbsp;46. After
the first year of the study, 78&nbsp;patients continued into an open&#8209;label
extension to week&nbsp;98.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the second clinical study (IMPACT&nbsp;2),
efficacy and safety of infliximab were studied in 200&nbsp;patients with active
psoriatic arthritis (&#8805;&nbsp;5&nbsp;swollen joints and &#8805;&nbsp;5&nbsp;tender
joints). Forty&nbsp;six percent of patients continued on stable doses of
methotrexate (&#8804;&nbsp;25&nbsp;mg/week). During the 24&#8209;week double&#8209;blind
phase, patients received either 5&nbsp;mg/kg infliximab or placebo at weeks&nbsp;0,
2, 6, 14, and 22 (100&nbsp;patients in each group). At week&nbsp;16,
47&nbsp;placebo patients with &lt;&nbsp;10% improvement from baseline in both
swollen and tender joint counts were switched to infliximab induction (early
escape). At week&nbsp;24, all placebo&#8209;treated patients crossed over to
infliximab induction. Dosing continued for all patients through week&nbsp;46.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Key efficacy results for IMPACT and IMPACT&nbsp;2
are shown in Table&nbsp;9 below:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=8 valign=top style='width:100.0%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;9</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Effects on ACR and PASI in IMPACT and IMPACT&nbsp;2</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="38%" colspan=4 valign=top style='width:38.86%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>IMPACT</span></p>
  </td>
  <td width="38%" colspan=3 valign=top style='width:38.68%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>IMPACT&nbsp;2*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Placebo
  (week&nbsp;16)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Infliximab
  (week&nbsp;16)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(week&nbsp;98)</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Placebo</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(week&nbsp;24)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Infliximab
  (week&nbsp;24)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(week&nbsp;54)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Patients randomised</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>N/A<sup>a</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>ACR response</span></p>
  <p class=MsoNormal><span lang=EN-GB>(% of patients)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB>N</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>78</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=bottom style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>ACR&nbsp;20
  response*</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5(10%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34
  (65%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>48
  (62%)</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>16
  (16%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>54
  (54%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>53
  (53%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=bottom style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>ACR&nbsp;50
  response*</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0(0%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>24
  (46%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>35
  (45%)</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4
  (4%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>41(41%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>33
  (33%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=bottom style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>ACR&nbsp;70
  response*</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0(0%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15
  (29%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27
  (35%)</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (2%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27
  (27%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>20
  (20%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PASI response</span></p>
  <p class=MsoNormal><span lang=EN-GB>(% of patients)<sup>b</sup></span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB>N</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>87</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>83</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>82</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=bottom style='width:22.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>PASI&nbsp;75
  response**</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.94%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.92%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1
  (1%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>50
  (60%)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.92%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40
  (48.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=8 valign=top style='width:100.0%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB style='font-size:9.0pt'>*&nbsp;&nbsp;&nbsp; ITT&#8209;analysis
  where subjects with missing data were included as non&#8209;responders.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;98
  data for IMPACT includes combined placebo crossover and infliximab patients
  who entered the open&#8209;label extension.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Based
  on patients with PASI &#8805;&nbsp;2.5 at baseline for IMPACT, and patients
  with &#8805;&nbsp;3% BSA psoriasis skin involvement at baseline in IMPACT&nbsp;2.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
  lang=EN-GB style='font-size:9.0pt'>**&nbsp; PASI&nbsp;75 response for IMPACT
  not included due to low N; p&nbsp;&lt;&nbsp;0.001 for infliximab vs. placebo
  at week&nbsp;24 for IMPACT&nbsp;2.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=136 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=0 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=78 style='border:none'></td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In IMPACT and IMPACT&nbsp;2, clinical
responses were observed as early as week&nbsp;2 and were maintained through
week&nbsp;98 and week&nbsp;54 respectively. Efficacy has been demonstrated with
or without concomitant use of methotrexate. Decreases in parameters of
peripheral activity characteristic of psoriatic arthritis (such as number of
swollen joints, number of painful/tender joints, dactylitis and presence of
enthesopathy) were seen in the infliximab&#8209;treated patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Radiographic changes were assessed in
IMPACT&nbsp;2. Radiographs of hands and feet were collected at baseline, weeks&nbsp;24
and&nbsp;54. Infliximab treatment reduced the rate of progression of peripheral
joint damage compared with placebo treatment at the week&nbsp;24 primary
endpoint as measured by change from baseline in total modified vdH&#8209;S
score (mean &plusmn; SD score was 0.82&nbsp;&plusmn;&nbsp;2.62 in the placebo
group compared with &#8209;0.70&nbsp;&plusmn;&nbsp;2.53 in the infliximab
group; p&nbsp;&lt;&nbsp;0.001). In the infliximab group, the mean change in
total modified vdH&#8209;S score remained below 0 at the week&nbsp;54
timepoint.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab&#8209;treated patients
demonstrated significant improvement in physical function as assessed by HAQ.
Significant improvements in health&#8209;related quality of life were also
demonstrated as measured by the physical and mental component summary scores of
the SF&#8209;36 in IMPACT&nbsp;2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult
psoriasis</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The efficacy of
infliximab was assessed in two multicenter, randomised, double&#8209;blind<b> </b>studies:
SPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface
Area [BSA] &#8805;&nbsp;10% and Psoriasis Area and Severity Index [PASI] score &#8805;&nbsp;12).
The primary endpoint in both studies was the percent of patients who achieved &#8805;&nbsp;75%
improvement in PASI from baseline at week&nbsp;10.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SPIRIT
evaluated the efficacy of infliximab induction therapy in 249&nbsp;patients
with plaque psoriasis that had previously received PUVA or systemic therapy.
Patients received either 3 or 5&nbsp;mg/kg infliximab or placebo infusions at
weeks&nbsp;0, 2 and 6. Patients with a PGA score &#8805;&nbsp;3 were eligible
to receive an additional infusion of the same treatment at week&nbsp;26.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In SPIRIT, </span><span
lang=EN-GB>the proportion of patients achieving PASI&nbsp;75 at week&nbsp;10
was 71.7% in the 3&nbsp;mg/kg infliximab group, 87.9% in the 5&nbsp;mg/kg
infliximab group, and 5.9% in the placebo group (p&nbsp;&lt;&nbsp;0.001). By
week&nbsp;26, twenty weeks after the last induction dose, 30% of patients in
the 5&nbsp;mg/kg group and 13.8% of patients in the 3&nbsp;mg/kg group were
PASI&nbsp;75 responders. Between weeks&nbsp;6 and 26, symptoms of psoriasis
gradually returned with a median time to disease relapse of &gt;&nbsp;20&nbsp;weeks.
No rebound was observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>EXPRESS evaluated the efficacy of
infliximab induction and maintenance therapy in 378&nbsp;patients with plaque
psoriasis. Patients received 5&nbsp;mg/kg infliximab&#8209; or placebo&#8209;infusions
at weeks&nbsp;0, 2 and 6 followed by maintenance therapy every 8&nbsp;weeks
through week&nbsp;22 in the placebo group and through week&nbsp;46 in the
infliximab group. A</span><span lang=EN-GB>t week&nbsp;24, the placebo group
crossed over to infliximab induction therapy (5&nbsp;mg/kg) followed by
infliximab maintenance therapy (5&nbsp;mg/kg).</span><span lang=EN-GB> Nail
psoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). </span><span
lang=EN-GB>Prior therapy with PUVA, methotrexate, ciclosporin, or acitretin had
been received by 71.4% of patients</span><span lang=EN-GB>, although they were
not necessarily therapy resistant</span><span lang=EN-GB>. </span><span
lang=EN-GB>Key results are presented in Table&nbsp;10. In infliximab treated
subjects, significant PASI&nbsp;50 responses were apparent at the first visit
(week&nbsp;2) and PASI&nbsp;75 responses by the second visit (week&nbsp;6).
Efficacy was similar in the subgroup of patients that were exposed to previous
systemic therapies compared to the overall study population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=598 colspan=3 valign=bottom style='width:448.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Table&nbsp;10</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Summary of PASI response, PGA response and percent
  of patients with all nails cleared at weeks&nbsp;10, 24 and 50. EXPRESS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=top style='width:236.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo &#8594; Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5&nbsp;mg/kg</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(at week&nbsp;24)</span></p>
  </td>
  <td width=112 valign=top style='width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infliximab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5&nbsp;mg/kg</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;10</span></b></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB>N</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>301</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;90% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1
  (1.3%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>172
  (57.1%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;75% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (2.6%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>242
  (80.4%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;50% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6
  (7.8%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>274
  (91.0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0) or minimal (1)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3
  (3.9%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>242
  (82.9%)<sup>ab</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0), minimal (1), or mild
  (2)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14
  (18.2%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>275
  (94.2%)<sup>ab</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;24</span></b></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB>N</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>77</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>276</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;90% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1
  (1.3%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>161
  (58.3%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;75% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3
  (3.9%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>227
  (82.2%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;50% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5
  (6.5%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>248
  (89.9%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0) or minimal (1)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2
  (2.6%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>203
  (73.6%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0), minimal (1), or mild
  (2)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15
  (19.5%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>246
  (89.1%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Week&nbsp;50</span></b></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt'><span lang=EN-GB>N</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>68</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>281</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;90% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34
  (50.0%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>127
  (45.2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;75% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>52
  (76.5%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>170
  (60.5%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&#8805;&nbsp;50% improvement</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61
  (89.7%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>193
  (68.7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0) or minimal (1)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>46
  (67.6%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>149
  (53.0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>PGA of cleared (0), minimal (1), or mild
  (2)</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>59
  (86.8%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>189
  (67.3%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>All
  nails cleared<sup>c</sup></span></b></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Week&nbsp;10</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1/65
  (1.5%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>16/235
  (6.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Week&nbsp;24</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3/65
  (4.6%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>58/223
  (26.0%)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=316 valign=bottom style='width:236.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Week&nbsp;50</span></p>
  </td>
  <td width=170 valign=bottom style='width:127.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27/64
  (42.2%)</span></p>
  </td>
  <td width=112 valign=bottom style='width:84.0pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>92/226
  (40.7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=598 colspan=3 valign=bottom style='width:448.4pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB style='layout-grid-mode:line'>a</span></sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>&nbsp;&nbsp;&nbsp;&nbsp; p&nbsp;&lt;&nbsp;0.001,
  for each infliximab treatment group vs. control.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB style='layout-grid-mode:line'>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>&nbsp;&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;292.</span></p>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB style='font-size:9.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; Analysis
  was based on subjects with nail psoriasis at baseline (81.8% of subjects).
  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Significant improvements from baseline were
demonstrated in DLQI (p&nbsp;&lt;&nbsp;0.001) and the physical and mental
component scores of the SF 36 (p&nbsp;&lt;&nbsp;0.001 for each component
comparison).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span lang=EN-GB>Paediatric
population</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
Crohn&#8217;s disease (6 to&nbsp;17&nbsp;years)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In the REACH study, 112&nbsp;patients (6 to
17&nbsp;years, median age 13.0&nbsp;years) with moderate to severe, active
Crohn&#8217;s disease (median paediatric CDAI of 40) and an inadequate response
to conventional therapies were to receive 5&nbsp;mg/kg infliximab at weeks&nbsp;0,
2, and 6. All patients were required to be on a stable dose of 6&#8209;MP, AZA
or MTX (35% were also receiving corticosteroids at baseline). Patients assessed
by the investigator to be in clinical response at week&nbsp;10 were randomised
and received 5&nbsp;mg/kg infliximab at either q8&nbsp;weeks or q12&nbsp;weeks
as a maintenance treatment regimen. If response was lost during maintenance
treatment, crossing over to a higher dose (10&nbsp;mg/kg) and/or shorter dosing
interval (q8&nbsp;weeks) was allowed. Thirty&nbsp;two (32) evaluable paediatric
patients crossed over (9&nbsp;subjects in the q8&nbsp;weeks and
23&nbsp;subjects in the q12&nbsp;weeks maintenance groups). Twenty&nbsp;four of
these patients (75.0%) regained clinical response after crossing over.</span></p>

<p class=MsoNormal><span lang=EN-GB>The proportion of subjects in clinical
response at week&nbsp;10 was 88.4% (99/112). The proportion of subjects
achieving clinical remission at week&nbsp;10 was 58.9% (66/112).</span></p>

<p class=MsoNormal><span lang=EN-GB>At week&nbsp;30, the proportion of subjects
in clinical remission was higher in the q8&nbsp;week (59.6%, 31/52) than the
q12&nbsp;week maintenance treatment group (35.3%, 18/51; p&nbsp;=&nbsp;0.013).
At week&nbsp;54, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8&nbsp;weeks
and q12&nbsp;weeks maintenance groups, respectively (p&nbsp;&lt;&nbsp;0.001).</span></p>

<p class=MsoNormal><span lang=EN-GB>Data about fistulas were derived from PCDAI
scores. Of the 22&nbsp;subjects that had fistulas at baseline, 63.6% (14/22),
59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week&nbsp;10,
30 and 54, respectively, in the combined q8&nbsp;weeks and q12&nbsp;weeks
maintenance groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, statistically and clinically
significant improvements in quality of life and height, as well as a
significant reduction in corticosteroid use, were observed versus baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
ulcerative colitis (6 to 17&nbsp;years)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of infliximab were
assessed in a multicenter, randomised, open&#8209;label, parallel&#8209;group
clinical study (C0168T72) in 60&nbsp;paediatric patients aged 6 through 17&nbsp;years
(median age 14.5&nbsp;years) with moderately to severely active ulcerative
colitis (Mayo score of 6 to 12; endoscopic subscore &#8805;&nbsp;2) with an
inadequate response to conventional therapies. At baseline 53% of patients were
receiving immunomodulator therapy (6&#8209;MP, AZA and/or MTX) and 62% of
patients were receiving corticosteroids. Discontinuation of immunomodulators
and corticosteroid taper were permitted after week&nbsp;0.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients received an induction regimen
of 5&nbsp;mg/kg infliximab at weeks&nbsp;0, 2, and 6. Patients who did not
respond to infliximab at week&nbsp;8 (n&nbsp;=&nbsp;15) received no further medicinal
product and returned for safety follow&#8209;up. At week&nbsp;8, 45&nbsp;patients
were randomised and received 5&nbsp;mg/kg infliximab at either q8&nbsp;weeks or
q12&nbsp;weeks as a maintenance treatment regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The proportion of patients in clinical
response at week&nbsp;8&nbsp;was 73.3% (44/60). Clinical response at week&nbsp;8
was similar between those with or without concomitant immunomodulator use at
baseline. Clinical remission at week&nbsp;8 was 33.3% (17/51) as measured by
the Paediatric Ulcerative Colitis Activity Index (PUCAI) score.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At week&nbsp;54, the proportion of patients
in clinical remission as measured by the PUCAI score was 38% (8/21) in the
q8&nbsp;week maintenance group and 18% (4/22) in the q12&nbsp;week maintenance
treatment group. </span><span lang=EN-GB>For patients receiving corticosteroids
at baseline, the proportion of patients in remission and not receiving
corticosteroids at week&nbsp;54 was 38.5% (5/13) for the q8&nbsp;week and 0%
(0/13) for the q12&nbsp;week maintenance treatment group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In this study, there were more patients in
the 12 to 17&nbsp;year age group than in the 6 to 11&nbsp;year age group (45/60
vs.15/60). While the numbers of patients in each subgroup are too small to draw
definitive conclusions about the effect of age, there was a higher number of
patients in the younger age group who stepped up in dose or discontinued
treatment due to inadequate efficacy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Other paediatric indications</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with Remicade in all subsets of
the paediatric population in rheumatoid arthritis, juvenile idiopathic
arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's
disease (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Single
intravenous infusions of 1, 3, 5, 10&nbsp;or 20&nbsp;mg/kg of infliximab
yielded dose proportional increases in the maximum serum concentration (C<sub>max</sub>)
and area under the concentration&#8209;time curve (AUC). The volume of
distribution at steady state (median&nbsp;V<sub>d </sub>of 3.0 to
4.1&nbsp;litres) was not dependent on the administered dose and indicated that
infliximab is predominantly distributed within the vascular compartment. No
time&#8209;dependency of the Pharmacokinetics was observed. The elimination
pathways for infliximab have not been characterised. Unchanged infliximab was
not detected in urine. No major age&#8209; or weight&#8209;related differences
in clearance or volume of distribution were observed in rheumatoid arthritis
patients. </span><span lang=EN-GB>The pharmacokinetics of infliximab in elderly
patients has not been studied. Studies have not been performed in patients with
liver or renal disease.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>At single
doses of 3, 5, or 10&nbsp;mg/kg, the median C<sub>max</sub> values were 77, 118
and 277&nbsp;micrograms/ml, respectively. The median terminal half&#8209;life
at these doses ranged from 8 to 9.5&nbsp;days. In most patients, infliximab
could be detected in the serum for at least 8&nbsp;weeks after the recommended
single dose of 5&nbsp;mg/kg for Crohn&#8217;s disease and the rheumatoid
arthritis maintenance dose of 3&nbsp;mg/kg every 8&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Repeated administration of infliximab (5&nbsp;mg/kg
at 0, 2 and 6&nbsp;weeks in fistulising Crohn&#8217;s disease, 3 or
10&nbsp;mg/kg every 4 or 8&nbsp;weeks in rheumatoid arthritis) resulted in a
slight accumulation of infliximab in serum after the second dose. No further
clinically relevant accumulation was observed. In most fistulising
Crohn&#8217;s disease patients, infliximab was detected in serum for
12&nbsp;weeks (range 4&#8209;28&nbsp;weeks) after administration of the
regimen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Population
pharmacokinetic analysis based on data obtained from patients with ulcerative
colitis (N&nbsp;=&nbsp;60), Crohn&#8217;s disease (N&nbsp;=&nbsp;112), juvenile
rheumatoid arthritis (N&nbsp;=&nbsp;117) and Kawasaki disease (N&nbsp;=&nbsp;16)
with an overall age range from 2&nbsp;months to 17&nbsp;years indicated that
exposure to infliximab was dependent on body weight in a non&#8209;linear way.
Following administration of 5&nbsp;mg/kg Remicade every 8&nbsp;weeks, the
predicted median steady&#8209;state infliximab exposure (area under
concentration&#8209;time curve at steady state, AUC<sub>ss</sub>) in paediatric
patients aged 6&nbsp;years to 17&nbsp;years was approximately 20% lower than
the predicted median steady&#8209;state drug exposure in adults. The median AUC<sub>ss</sub>
in paediatric patients aged 2&nbsp;years to less than 6&nbsp;years was
predicted to be approximately 40% lower than that in adults, although the
number of patients supporting this estimate is limited.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infliximab does not cross react with TNF</span><sub><span
lang=EN-GB style='font-family:Symbol'>a</span></sub><span lang=EN-GB> from
species other than human and chimpanzees. Therefore, conventional preclinical
safety data with infliximab are limited. In a developmental toxicity study conducted
in mice using an analogous antibody that selectively inhibits the functional
activity of mouse TNF</span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB>, there was no indication of maternal toxicity, embryotoxicity or
teratogenicity. In a fertility and general reproductive function study, the
number of pregnant mice was reduced following administration of the same
analogous antibody. It is not known whether this finding was due to effects on
the males and/or the females. <span style='layout-grid-mode:line'>In a 6&#8209;month
repeated dose toxicity study in mice, using the same analogous antibody against
mouse TNF</span></span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB style='layout-grid-mode:line'>, crystalline deposits were observed
on the lens capsule of some of the treated male mice. No specific
ophthalmologic examinations have been performed in patients to investigate the
relevance of this finding for humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>Long&#8209;term studies have not been
performed to evaluate the carcinogenic potential of infliximab. Studies in mice
deficient in TNF</span><sub><span lang=EN-GB style='font-family:Symbol'>a</span></sub><span
lang=EN-GB> demonstrated no increase in tumours when challenged with known
tumour initiators and/or promoters.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sucrose</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal><span lang=EN-GB>Monobasic sodium phosphate</span></p>

<p class=MsoNormal><span lang=EN-GB>Dibasic sodium phosphate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Before
reconstitution:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;years
at 2<span class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&#8211;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade may be stored at temperatures up
to a maximum of 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C for a single period of up
to 6&nbsp;months, but not exceeding the original expiry date. The new expiry
date must be written on the carton. Upon removal from refrigerated storage,
Remicade must not be returned to refrigerated storage.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>After reconstitution and dilution:</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Chemical and physical in use stability of
the diluted solution has been demonstrated for up to 28&nbsp;days at 2<span
class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C to 8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C and for an additional 24&nbsp;hours
at 25<span class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C after removal from
refrigeration. From a microbiological point of view, the infusion solution should
be administered immediately, in use storage times and conditions prior to use
are the responsibility of the user and would normally not be longer than
24&nbsp;hours at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C to 8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C, unless
reconstitution/dilution has been taken place in controlled and validated
aseptic conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2<span
class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&#8209;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions up to 25<span
class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:11">&nbsp;</del></span>&deg;C before reconstitution of
the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after reconstitution
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of
container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Type&nbsp;1 glass vial with rubber stopper
and aluminium crimp protected by a plastic cap.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is available in packs of 1, 2, 3,
4 or 5&nbsp;vials.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal and other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the dose and the
number of Remicade vials needed. Each Remicade vial contains 100&nbsp;mg
infliximab. Calculate the total volume of reconstituted Remicade solution
required.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Under aseptic conditions,
reconstitute each Remicade vial with 10&nbsp;ml of water for injections, using
a syringe equipped with a 21&#8209;gauge (0.8&nbsp;mm) or smaller needle.
Remove flip&#8209;top from the vial and wipe the top with a 70% alcohol swab.
Insert the syringe needle into the vial through the centre of the rubber
stopper and direct the stream of water for injections to the glass wall of the
vial. Gently swirl the solution by rotating the vial to dissolve the
lyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.
Foaming of the solution on reconstitution is not unusual. Allow the
reconstituted solution to stand for 5&nbsp;minutes. Check that the solution is
colourless to light yellow and opalescent. The solution may develop a few fine
translucent particles, as infliximab is a protein. Do not use if opaque
particles, discolouration, or other foreign particles are present.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dilute the total volume of
the reconstituted Remicade solution dose to 250&nbsp;ml with sodium chloride
9&nbsp;mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted
Remicade solution with any other diluent. The dilution can be accomplished by
withdrawing a volume of the sodium chloride 9&nbsp;mg/ml (0.9%) solution for
infusion from the 250&#8209;ml glass bottle or infusion bag equal to the volume
of reconstituted Remicade. Slowly add the total volume of reconstituted
Remicade solution to the 250&#8209;ml infusion bottle or bag. Gently mix. For
volumes greater than 250&nbsp;ml, either use a larger infusion bag (e.g. 500&nbsp;ml,
1000&nbsp;ml) or use multiple 250&nbsp;ml infusion bags to ensure that the
concentration of the infusion solution does not exceed 4&nbsp;mg/ml. If stored
refrigerated after reconstitution and dilution, the infusion solution must be
allowed to equilibrate at room temperature to 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:12">&nbsp;</del></span>&deg;C for 3&nbsp;hours prior to
Step&nbsp;4 (infusion). Storage beyond 24&nbsp;hours at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:12">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:12">&nbsp;</del></span>&#8209;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:12">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:12">&nbsp;</del></span>&deg;C applies to preparation of
Remicade in the infusion bag only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the infusion
solution over a period of not less than the infusion time recommended (see
section&nbsp;4.2). Use only an infusion set with an in&#8209;line, sterile, non&#8209;pyrogenic,
low protein&#8209;binding filter (pore size 1.2&nbsp;micrometre or less). Since
no preservative is present, it is recommended that the administration of the
solution for infusion is to be started as soon as possible and within
3&nbsp;hours of reconstitution and dilution. If not used immediately, in use
storage times and conditions prior to use are the responsibility of the user and
would normally not be longer than 24&nbsp;hours at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:13">&nbsp;</del></span>&deg;C to 8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:13">&nbsp;</del></span>&deg;C, unless reconstitution/dilution
has been taken place in controlled and validated aseptic conditions, (see
section&nbsp;6.3 above). Do not store any unused portion of the infusion
solution for reuse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No physical biochemical
compatibility studies have been conducted to evaluate the co&#8209;administration
of Remicade with other agents. Do not infuse Remicade concomitantly in the same
intravenous line with other agents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect Remicade for
particulate matter or discolouration prior to administration. Do not use if
visibly opaque particles, discolouration or foreign particles are observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicinal product
or waste material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Janssen Biologics B.V.</span></p>

<p class=MsoNormal><span lang=DE>Einsteinweg 101</span></p>

<p class=MsoNormal><span lang=DE>2333 CB Leiden</span></p>

<p class=MsoNormal><span lang=DE>The Netherlands</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=DE>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>EU/1/99/116/001</span></p>

<p class=MsoNormal><span lang=DE>EU/1/99/116/002</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/99/116/003</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/99/116/004</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/99/116/005</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 13 August
1999.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Date of latest renewal: 2 July 2009.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Detailed
information on this product is available on the website of the European
Medicines Agency <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S) OF THE BIOLOGICAL
ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.55pt;margin-bottom:
0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S) OF
THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Names and
addresses of the manufacturer(s) of the biological active substance(s)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Janssen
Biologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Janssen Biotech
Inc., 200 Great Valley Parkway Malvern, Pennsylvania 19355&#8209;1307, United
States of America</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Name and
address of the manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Janssen Biologics B.V., Einsteinweg 101,
2333 CB Leiden, The Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">S</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">s</ins></span>afety <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">U</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">u</ins></span>pdate <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">R</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">r</ins></span>eports<span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11"> (PSURs)</ins></span></span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of <span
class=msoIns><ins cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">PSURs</ins></span><span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:11">periodic safety update reports</del></span> for
this medicinal product are set out in the list of Union reference dates (EURD
list) provided for under Article 107c(7) of Directive 2001/83</span><span
lang=EN-GB>/EC and any subsequent updates published on the European medicines
web&#8209;portal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:12">M</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:12">m</ins></span>anagement <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:12">P</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:12">p</ins></span>lan (RMP)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The <span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:13">marketing au</ins></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:29">thorisation holder (</ins></span>MAH<span
class=msoIns><ins cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:29">)</ins></span> shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the <span class=msoDel><del cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:31">M</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:31">m</ins></span>arketing <span class=msoDel><del
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:31">A</del></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-24T08:31">a</ins></span>uthorisation and any agreed subsequent
updates of the RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The educational programme consists of a patient
reminder card to be held by the patient. The card is aimed at both serving as a
reminder to record the dates and outcomes of specific tests and to facilitate
the patient sharing of special information with healthcare professionals(s) (HCPs)
treating the patient about on&#8209;going treatment with the product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>The patient reminder card </span></b><span
lang=EN-GB>shall contain the following key messages:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A reminder to patients to show the patient reminder
card to all treating HCPs, including in conditions of emergency, and a message for
HCPs that the patient is using Remicade</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A statement that the brand name and batch number
should be recorded</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Provision to record the type, date, and result
of TB screenings</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>That treatment with Remicade may increase the
risks of serious infections/sepsis, opportunistic infections, tuberculosis,
hepatitis B reactivation, and BCG breakthrough in infants with <i>in utero</i>
exposure to infliximab, and when to seek attention from a HCP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Contact details of the prescriber</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>A.
LABELLING</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE
OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Remicade 100&nbsp;mg powder for concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>infliximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 100&nbsp;mg of
infliximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution one ml contains 10&nbsp;mg
of infliximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Excipients: sucrose, polysorbate&nbsp;80, monobasic
sodium phosphate and dibasic sodium phosphate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>Powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;vial 100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=DE style='background:silver'>2&nbsp;vials
100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=DE style='background:silver'>3&nbsp;vials
100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=DE style='background:silver'>4&nbsp;vials
100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>5&nbsp;vials
100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Intravenous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP, if not
refrigerated ___________________</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Can be stored at room temperature (up to 25<span
class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:16">&nbsp;</del></span>&deg;C) for a single period up
to 6&nbsp;months, but not exceeding the original expiry date.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Janssen
Biologics B.V.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Einsteinweg
101</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2333 CB
Leiden</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EU/1/99/116/001
<span style='background:silver'>1&nbsp;vial 100&nbsp;mg</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>EU/1/99/116/002 2&nbsp;vials 100&nbsp;mg</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>EU/1/99/116/003 3&nbsp;vials 100&nbsp;mg</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>EU/1/99/116/004 4&nbsp;vials 100&nbsp;mg</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:silver'>EU/1/99/116/005 5&nbsp;vials 100&nbsp;mg</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>Justification for
not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC<span
class=msoDel><del cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:16">:</del></span></span></p>

<p class=MsoNormal><span lang=EN-GB>SN<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:16">:</del></span></span></p>

<p class=MsoNormal><span lang=EN-GB>NN<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:16">:</del></span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR
ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Remicade
100&nbsp;mg powder for concentrate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>infliximab</span></p>

<p class=MsoNormal><span lang=EN-GB>IV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For intravenous
use after reconstitution and dilution.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS BY WEIGHT, BY VOLUME
OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=619
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:16.0pt'>Remicade</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>infliximab</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:16.0pt'>Patient Reminder Card</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Name patient:</span></p>
  <p class=MsoNormal><span lang=EN-GB>Name doctor:</span></p>
  <p class=MsoNormal><span lang=EN-GB>Telephone number doctor:</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>This patient reminder card contains
  important safety information that you need to be aware of before and during
  treatment with Remicade.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Show this card to any doctor involved in
  your treatment.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Please read the Remicade &#8216;Package
  Leaflet&#8217; carefully before you start using this medicine.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Date of Remicade therapy initiation:</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Current administrations:</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>It is important that you and your doctor
  record the brand name and batch number of your medicine.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Ask your doctor to record the type and
  date of last screening(s) for tuberculosis (TB) below:</span></p>
  <p class=MsoNormal><span lang=EN-GB>Test&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test</span></p>
  <p class=MsoNormal><span lang=EN-GB>Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date</span></p>
  <p class=MsoNormal><span lang=EN-GB>Result:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Result:</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Please make sure you also have a list of
  all other medicines that you are using with you at any visit to a healthcare
  professional.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>List of allergies:</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>List of other medicines:</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:14.0pt'>Infections</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>Before treatment with Remicade</span></b></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Tell your doctor if you have an infection even
  if it is a very minor one</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>It is very important that you tell your doctor
  if you have ever had TB, or if you have been in close contact with someone
  who has had TB. Your doctor will test you to see if you have TB. Ask your
  doctor to record the type and date of your last screening(s) for TB on the
  card</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Tell your doctor if you have hepatitis B or if
  you know or suspect you are a carrier of the hepatitis B virus.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>During treatment with Remicade</span></b></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Tell your doctor straight away if you have
  signs of an infection. Signs include a fever, feeling tired, (persistent)
  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,
  dental problems, burning when urinating or &#8216;flu&#8209;like&#8217;
  signs.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:14.0pt'>Pregnancy and
  Vaccinations</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>In case you have received Remicade while you
  were pregnant, it is important that you inform your baby&#8217;s doctor about
  it before your baby receives any vaccine. Your baby should not receive a
  &#8216;live vaccine&#8217;, such as BCG (used to prevent tuberculosis) within
  6&nbsp;months after birth.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Keep this card with you for 4&nbsp;months
  after your dose of Remicade, or in case of pregnancy for at least
  6&nbsp;months after the birth of your baby. Side effects may occur a long
  time after your last dose.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>B.
PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><span
lang=EN-GB>Remicade </span></b><b><span lang=EN-GB>100&nbsp;mg powder for
concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
lang=EN-GB>infliximab</span></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Read all
of this leaflet carefully before you start using this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will also give you a patient reminder
card, which contains important safety information you need to be aware of
before and during your treatment with Remicade.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What is
in this leaflet:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Remicade is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use Remicade</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
Remicade will be given</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Remicade</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Remicade
is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade contains the active substance
infliximab. Infliximab is a monoclonal antibody &#8211; a type of protein that
attaches to a specific target in the body called TNF (tumour necrosis factor)
alpha.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade belongs to a group of medicines
called &#8216;TNF blockers&#8217;. It is used in adults for the following
inflammatory diseases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rheumatoid arthritis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Psoriatic arthritis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ankylosing spondylitis (Bechterew&#8217;s
disease)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Psoriasis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is also used in adults and
children 6&nbsp;years of age or older for:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Crohn&#8217;s disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ulcerative colitis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade works by selectively attaching to
TNF alpha and blocking its action. TNF alpha is involved in inflammatory
processes of the body so blocking it can reduce the inflammation in your body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rheumatoid
arthritis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Rheumatoid arthritis is an inflammatory
disease of the joints. If you have active rheumatoid arthritis you will first
be given other medicines. If these medicines do not work well enough, you will
be given Remicade which you will take in combination with another medicine
called methotrexate to:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduce the signs and symptoms of your disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Slow down the damage in your joints</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Improve your physical function.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Psoriatic
arthritis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Psoriatic arthritis is an inflammatory
disease of the joints, usually accompanied by psoriasis. If you have active
psoriatic arthritis you will first be given other medicines. If these medicines
do not work well enough, you will be given Remicade to:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduce the signs and symptoms of your disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Slow down the damage in your joints</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Improve your physical function.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Ankylosing
spondylitis (Bechterew&#8217;s disease)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Ankylosing spondylitis is an inflammatory
disease of the spine. If you have ankylosing spondylitis you will first be given
other medicines. If these medicines do not work well enough, you will be given
Remicade to:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduce the signs and symptoms of your disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Improve your physical function.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Psoriasis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Psoriasis is an inflammatory disease of the
skin. If you have moderate to severe plaque psoriasis, you will first be given
other medicines or treatments, such as phototherapy. If these medicines or
treatments do not work well enough, you will be given Remicade to reduce the signs
and symptoms of your disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Ulcerative
colitis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Ulcerative colitis is an inflammatory
disease of the bowel. If you have ulcerative colitis you will first be given
other medicines. If these medicines do not work well enough, you will be given
Remicade to treat your disease.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Crohn&#8217;s
disease</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Crohn&#8217;s disease is an inflammatory
disease of the bowel. If you have Crohn&#8217;s disease you will first be given
other medicines. If these medicines do not work well enough, you will be given
Remicade to:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Treat active Crohn&#8217;s disease</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduce the number of abnormal openings
(fistulae) between your bowel and your skin that have not been controlled by
other medicines or surgery.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you use Remicade</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>You
should not be given Remicade if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You are allergic to infliximab or to any of the
other ingredients in Remicade (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You are allergic (hypersensitive) to proteins
that come from mice.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have tuberculosis (TB) or another serious
infection such as pneumonia or sepsis.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have heart failure that is moderate or
severe.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use Remicade if any of the above
applies to you. If you are not sure, talk to your doctor before you are given
Remicade.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor before or during
treatment with Remicade if you have:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Had treatment with Remicade before</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have had treatment with
Remicade in the past and are now starting Remicade treatment again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>If you have had
a break in your Remicade treatment of more than 16&nbsp;weeks, there is a higher
risk for allergic reactions when you start the treatment again.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor before you are given Remicade if
you have an infection even if it is a very minor one.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor before you are given Remicade if
you have ever lived in or travelled to an area where infections called histoplasmosis,
coccidioidomycosis, or blastomycosis are common. These infections are caused by
specific types of fungi that can affect the lungs or other parts of your body.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You may get infections more easily when you are
being treated with Remicade. If you are 65 or older, you have a greater risk.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>These infections may be serious and include
tuberculosis, infections caused by viruses, fungi, bacteria, or other organisms
in the environment and sepsis that may be life&#8209;threatening.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your
doctor straight away if you get signs of infection during treatment with
Remicade. Signs include fever, cough, flu&#8209;like signs, feeling unwell, red
or hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping
Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Tuberculosis (TB)</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is very important that you tell your doctor
if you have ever had TB or if you have been in close contact with someone who
has had or has TB.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will test you to see if you have TB.
Cases of TB have been reported in patients treated with Remicade, even in patients
who have already been treated with medicines for TB. Your doctor will record
these tests on your patient reminder card.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If your doctor feels that you are at risk for
TB, you may be treated with medicines for TB before you are given Remicade.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your doctor
straight away if you get signs of TB during treatment with Remicade. Signs
include persistent cough, weight loss, feeling tired, fever, night sweats.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Hepatitis B virus</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor before you are given Remicade if
you are a carrier of hepatitis B or have ever had it.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you think you might be at
risk of contracting hepatitis B.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor should test you for hepatitis B
virus.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Treatment with TNF blockers such as Remicade may
result in reactivation of hepatitis B virus in patients who carry this virus,
which can be life&#8209;threatening in some cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Heart problems</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have any heart problems,
such as mild heart failure.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will want to closely monitor your
heart.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your
doctor straight away if you get new or worsening signs of heart failure during
treatment with Remicade. Signs include shortness of breath or swelling of your
feet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Cancer and lymphoma</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor before you are given Remicade if
you have or have ever had lymphoma (a type of blood cancer) or any other
cancer.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Patients with severe rheumatoid arthritis, who
have had the disease for a long time, may be at higher risk of developing
lymphoma.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Children and adults taking Remicade may have an
increased risk of developing lymphoma or another cancer.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some patients who have received TNF&#8209;blockers,
including Remicade have developed a rare type of cancer called hepatosplenic T&#8209;cell
lymphoma. Of these patients, most were teenage boys or young men and most had
either Crohn&#8217;s disease or ulcerative colitis. This type of cancer has
usually resulted in death. Almost all patients had also received medicines
containing azathioprine or 6&#8209;mercaptopurine in addition to TNF&#8209;blockers.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some patients treated with infliximab have
developed certain kinds of skin cancer. If there are any changes in your skin
or growths on the skin during or after therapy, tell your doctor.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some women being treated for rheumatoid
arthritis with Remicade have developed cervical cancer. For women taking
Remicade including those over 60&nbsp;years of age, your doctor may recommend
regular screening for cervical cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Lung disease or heavy smoking</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor before you are given Remicade if
you have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or
if you are a heavy smoker.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Patients with COPD and patients who are heavy
smokers may have a higher risk of developing cancer with Remicade treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Nervous system disease</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have or have ever had a
problem that affects your nervous system before you are given Remicade. This
includes multiple sclerosis, Guillain&#8209;Barre syndrome, if you have fits or
have been diagnosed with &#8216;optic neuritis&#8217;.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your
doctor straight away if you get symptoms of a nerve disease during treatment
with Remicade. Signs include changes in your vision, weakness in your arms or
legs, numbness or tingling in any part of your body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Abnormal skin openings</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you have any abnormal skin
openings (fistulae) before you are given Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Vaccinations</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Talk to your doctor if you recently have had or
are due to have a vaccine.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You should receive recommended vaccinations
before starting Remicade treatment. You may receive some vaccines during
treatment with Remicade but you should not receive live vaccines (vaccines that
contain a living but weakened infectious agent) while using Remicade because
they may cause infections.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you received Remicade while you were
pregnant, your baby may also be at higher risk for getting an infection with
live vaccines for up to six months after birth. It is important that you tell
your baby's doctors and other healthcare professionals about your Remicade use
so they can decide when your baby should receive any vaccine, including live vaccines
such as BCG (used to prevent tuberculosis). For more information see section on
Pregnancy and breast&#8209;feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Therapeutic infectious agents</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Talk to you doctor if you have recently received
or are scheduled to receive treatment with a therapeutic infectious agent (such
as BCG instillation used for the treatment of cancer).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Operations or dental procedures</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor if you are going to have any
operations or dental procedures.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your surgeon or dentist that you are having
treatment with Remicade by showing them your patient reminder card.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Liver problems</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some patients receiving Remicade have developed
serious liver problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your
doctor straight away if you get symptoms of liver problems during treatment
with Remicade. Signs include yellowing of the skin and eyes, dark-brown</span><span
lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB>coloured urine,
pain or swelling in the upper right side of the stomach area, joint pain, skin
rashes, or fever.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Low blood counts</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In some patients receiving Remicade, the body
may not make enough of the blood cells that help fight infections or help stop
bleeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor straight away if you get
symptoms of low blood counts during treatment with Remicade. Signs include persistent
fever, bleeding or bruising more easily, small red or purple spots caused by bleeding
under the skin, or looking pale.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>Immune system disorder</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some patients receiving Remicade have developed
symptoms of an immune system disorder called lupus.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Tell your
doctor straight away if you develop symptoms of lupus during treatment with
Remicade. Signs include joint pain or a rash on cheeks or arms that is
sensitive to the sun.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><u><span
lang=EN-GB>The information above also applies to children and adolescents. In
addition:</span></u></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Some children and teenage patients who have
received TNF&#8209;blockers such as Remicade have developed cancers, including
unusual types, which sometimes resulted in death.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>More children taking Remicade developed
infections as compared to adults.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Children should receive recommended vaccinations
before starting Remicade treatment. Children may receive some vaccines during treatment
with Remicade but should not receive live vaccines while using Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are not sure if any of the above
apply to you, talk to your doctor before you are given Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Remicade</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Patients who have inflammatory diseases
already take medicines to treat their problem. These medicines may cause side
effects. Your doctor will advise you what other medicines you must keep using
while you are having Remicade.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor if you are using or have
recently used any other medicines, including any other medicines to treat
Crohn&#8217;s disease, ulcerative colitis, rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis or psoriasis or medicines obtained without a
prescription, such as vitamins and herbal medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In particular, tell your doctor if you are
using any of the following medicines:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Medicines that affect your immune system.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kineret (anakinra). Remicade and Kineret should
not be used together.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Orencia (abatacept). Remicade and Orencia should
not be used together.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While using Remicade you should not receive
live vaccines. If you were using Remicade during pregnancy, tell your
baby&#8217;s doctor and other healthcare professionals caring for your baby
about your Remicade use before the baby receives any vaccines.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you are
not sure if any of the above apply to you, talk to your doctor or pharmacist
before using Remicade.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast&#8209;feeding, and fertility</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are pregnant or breast&#8209;feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine. Remicade</span><span lang=EN-GB> </span><span
lang=EN-GB>should only be used during pregnancy if your doctor feels it is
necessary for you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You should avoid getting pregnant when you are
being treated with Remicade and for 6&nbsp;months after you stop being treated
with it. Discuss the use of contraception during this time with your doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not breast&#8209;feed when you are being
treated with Remicade or for 6&nbsp;months after your last treatment with
Remicade.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you received Remicade during your pregnancy,
your baby may have a higher risk for getting an infection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important that you tell your baby&#8217;s
doctors and other healthcare professionals about your Remicade use before your
baby is given any vaccine. If you received Remicade while pregnant, giving BCG
vaccine (used to prevent tuberculosis) to your baby within 6&nbsp;months after
birth may result in infection with serious complications, including death. Live
vaccines such as BCG should not be given to your baby within 6&nbsp;months
after birth. For more information see section on vaccination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severely decreased numbers of white blood cells
have been reported in infants born to women treated with Remicade during
pregnancy. If your baby has continual fevers or infections, contact your
baby&#8217;s doctor immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is not likely to affect your
ability to drive or use tools or machines. If you feel tired, dizzy, or unwell
after having Remicade, do not drive or use any tools or machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Remicade contains
sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Remicade contains less than 1&nbsp;mmol sodium
(23&nbsp;mg) per dose, that is to say essentially &#8216;sodium&#8209;free&#8217;.
However, before Remicade is given to you, it is mixed with a solution that
contains sodium. Talk to your doctor if you are on a low salt diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How Remicade
will be given</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rheumatoid
arthritis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The usual dose is 3&nbsp;mg for every kg of
body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Psoriatic
arthritis, ankylosing spondylitis (Bechterew&#8217;s disease), psoriasis,
ulcerative colitis and Crohn's disease</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The usual dose is 5&nbsp;mg for every kg of
body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How
Remicade is given</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Remicade will be given to you by your doctor or
nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor or nurse will prepare the medicine
for infusion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The medicine will be given as an infusion (drip)
(over 2&nbsp;hours) into one of your veins, usually in your arm. After the
third treatment, your doctor may decide to give your dose of Remicade over
1&nbsp;hour.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You will be monitored while you are given
Remicade and also for 1 to 2&nbsp;hours afterwards.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How much
Remicade is given</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The doctor will decide your dose and how often
you will be given Remicade. This will depend on your disease, weight and how
well you respond to Remicade.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The table below shows how often you will usually
have this medicine after your first dose.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=232 valign=top style='width:174.0pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2<sup>nd</sup> dose</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2&nbsp;weeks after your 1<sup>st</sup> dose</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=232 valign=top style='width:174.0pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3<sup>rd</sup> dose</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>6&nbsp;weeks after your 1<sup>st</sup> dose</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=232 valign=top style='width:174.0pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Further doses</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Every 6 to 8&nbsp;weeks depending on your
  disease </span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Use in
children and adolescents</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Remicade
should only be used in children if they are being treated for Crohn&#8217;s
disease or ulcerative colitis. These children must be 6&nbsp;years of age or
older.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
are given too much Remicade</span></b></p>

<p class=MsoNormal><span lang=EN-GB>As this medicine is being given by your
doctor or nurse, it is unlikely that you will be given too much. There are no
known side effects of having too much of Remicade.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget or miss your Remicade infusion</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you forget or miss an appointment to
receive Remicade, make another appointment as soon as possible.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them. Most side effects are mild to
moderate. However some patients may experience serious side effects and may
require treatment. Side effects may also occur after your treatment with Remicade
has stopped.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor straight away if you notice any of the following:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of an allergic reaction</span></b><span
lang=EN-GB> such as swelling of your face, lips, mouth or throat which may
cause difficulty in swallowing or breathing, skin rash, hives, swelling of the
hands, feet or ankles. Some of these reactions may be serious or
life-threatening. An allergic reaction could happen within 2&nbsp;hours of your
injection or later. More signs of allergic side effects that may happen up to
12&nbsp;days after your injection include pain in the muscles, fever, joint or
jaw pain, sore throat or headache.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of a heart problem</span></b><span
lang=EN-GB> such as chest discomfort or pain, arm pain, stomach pain, shortness
of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea
(feeling sick), vomiting, fluttering or pounding in your chest, a fast or a
slow heartbeat, and swelling of your feet.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of infection (including TB)</span></b><span
lang=EN-GB> such as fever, feeling tired, cough which may be persistent,
shortness of breath, flu&#8209;like symptoms, weight loss, night sweats,
diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental
problems or burning sensation when urinating.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Possible signs of cancer</span></b><span
lang=EN-GB> including but not limited to swelling of lymph nodes, weight loss,
fever, unusual skin nodules, changes in moles or skin colouring, or unusual
vaginal bleeding.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of a lung problem</span></b><span
lang=EN-GB> such as coughing, breathing difficulties or tightness in the chest.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of a nervous system problem (including
eye problems)</span></b><span lang=EN-GB> such as signs of a stroke (sudden
numbness or weakness of your face, arm or leg, especially on one side of your
body; sudden confusion, trouble speaking or understanding; trouble seeing in
one or both eyes, trouble walking, dizziness, loss of balance or coordination
or a severe headache), fits, tingling/numbness in any part of your body, or weakness
in arms or legs, changes in eyesight such as double vision or other eye
problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of a liver problem</span></b><span
lang=EN-GB> (including hepatitis B infection when you have had hepatitis B in
the past) such as yellowing of the skin or eyes, dark&#8209;brown coloured urine,
pain or swelling in the upper right side of the stomach area, joint pain, skin
rashes, or fever.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of an immune system disorder </span></b><span
lang=EN-GB>such as joint pain or a rash on cheeks or arms that is sensitive to
the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of low blood counts</span></b><span
lang=EN-GB> such as persistent fever, bleeding or bruising more easily, small
red or purple spots caused by bleeding under the skin, or looking pale.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Signs of serious skin problems </span></b><span
lang=EN-GB>such as reddish-target-like spots or circular patches often with
central blisters on the trunk, large areas of peeling and shedding
(exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small
pus-filled bumps that can spread over the body. These skin reactions can be accompanied
by fever.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor straight away if you
notice any of the above.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following side effects have been
observed with Remicade:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Very
common: may affect more than 1&nbsp;in 10&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stomach pain, feeling sick</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Viral infections such as herpes or flu</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Upper respiratory infections such as sinusitis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Side effect due to an infusion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Common:
may affect up to 1&nbsp;in 10&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Changes in how your liver works, increase in
liver enzymes (shown in blood tests)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Lung or chest infections such as bronchitis or
pneumonia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Difficult or painful breathing, chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bleeding in the stomach or intestines,
diarrhoea, indigestion, heartburn, constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nettle&#8209;type rash (hives), itchy rash or
dry skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Balance problems or feeling dizzy</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, increased sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Circulation problems such as low or high blood
pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bruising, hot flush or nosebleed, warm, red skin
(flushing)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling tired or weak</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bacterial infections such as blood poisoning,
abscess or infection of the skin (cellulitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infection of the skin due to a fungus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blood problems such as anaemia or low white
blood cell count</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swollen lymph nodes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Depression, problems sleeping</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eye problems, including red eyes and infections</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fast heart beat (tachycardia) or palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain in the joints, muscles or back</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Urinary tract infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Psoriasis, skin problems such as eczema and hair
loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reactions at the injection site such as pain,
swelling, redness or itching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Chills, a build up of fluid under the skin causing
swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling numb or having a tingling feeling.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon:
may affect up to 1&nbsp;in 100&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shortage of blood supply, swelling of a vein</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Collection of blood outside the blood vessels (haematoma)
or bruising</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin problems such as blistering, warts,
abnormal skin colouration or pigmentation, or swollen lips, or thickening of the
skin, or red, scaly, and flaky skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reactions (e.g. anaphylaxis), an
immune system disorder called lupus, allergic reactions to foreign proteins</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wounds taking longer to heal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling of the liver (hepatitis) or gall
bladder, liver damage</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling forgetful, irritable, confused, nervous</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eye problems including blurred or reduced
vision, puffy eyes or sties</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>New or worsening heart failure, slow heart rate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fainting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Convulsions, nerve problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A hole in the bowel or blockage of the
intestine, stomach pain or cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling of your pancreas (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fungal infections such as yeast infection or
fungal infection of the nails</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Lung problems (such as oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fluid around the lungs (pleural effusion)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Narrowed airway in the lungs, causing difficulty
breathing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflamed lining of the lung, causing sharp chest
pains that feel worse with breathing (pleurisy)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tuberculosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney infections</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low platelet count, too many white blood cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infections of the vagina</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blood test result showing
&#8216;antibodies&#8217; against your own body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rare: may
affect up to 1&nbsp;in 1,000&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A type of blood cancer (lymphoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your blood not supplying enough oxygen to your
body, circulation problems such as narrowing of a blood vessel</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the lining of the brain
(meningitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infections due to a weakened immune system</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hepatitis B infection when you have had
hepatitis B in the past</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflamed liver caused by a problem with the
immune system (autoimmune hepatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Liver problem that causes yellowing of the skin
or eyes (jaundice)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal tissue swelling or growth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="OLE_LINK3"><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction that may cause loss of
consciousness and could be life-threatening (anaphylactic shock)</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling of small blood vessels (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune disorders that could affect the lungs,
skin and lymph nodes (such as sarcoidosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Collections of immune cells resulting from an
inflammatory response (granulomatous lesions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Lack of interest or emotion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Serious skin problems such as toxic epidermal
necrolysis, Stevens&#8209;Johnson Syndrome and acute generalised exanthematous
pustulosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Other skin problems such as erythema multiforme,
lichenoid reactions (itchy reddish-purple skin rash and/or threadlike
white-grey lines on mucous membranes), blisters and peeling skin, or boils
(furunculosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Serious nervous system disorders such as
transverse myelitis, multiple sclerosis&#8209;like disease, optic neuritis and
Guillain&#8209;Barr&eacute; syndrome</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation in the eye that may cause changes
in the vision, including blindness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fluid in the lining of the heart (pericardial
effusion)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Serious</span><span lang=EN-GB> lung problems
(such as interstitial lung disease)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Melanoma (a type of skin cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cervical cancer</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low blood counts, including a severely decreased
number of white blood cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Small red or purple spots caused by bleeding under
the skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal values of a blood protein called
&#8216;complement factor&#8217; which is part of the immune system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Not
known: frequency cannot be estimated from the available data</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cancer in children and adults</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A rare blood cancer affecting mostly teenage boys
or young men (hepatosplenic T&#8209;cell lymphoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Liver failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Merkel cell carcinoma (a type of skin cancer)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-18T11:09">Ka</ins></span><span class=msoIns><ins
cite="mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]"
datetime="2020-08-18T11:10">posi&#8217;s sarcoma, a rare cancer related to
infection with human herpes virus 8. Kaposi&#8217;s sarcoma most commonly
appears as purple lesions on the skin.</ins></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Worsening of a condition called dermatomyositis
(seen as a skin rash accompanying muscle weakness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stroke</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Temporary loss of sight during or within 2&nbsp;hours
of infusion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infection due to a live vaccine because of a
weakened immune system.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Additional
side effects in children and adolescents</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Children who
took Remicade for Crohn&#8217;s disease showed some differences in side effects
compared with adults who took Remicade for Crohn's disease. The side effects
that happened more in children were: low red blood cells (anaemia), blood in
stool, low overall levels of white blood cells (leucopenia), redness or
blushing (flushing), viral infections, low levels of white blood cells that
fight infection (neutropenia), bone fracture, bacterial infection and allergic
reactions of the breathing tract.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you get
any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><a name="_Hlk503423848"><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Remicade</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade will generally be stored by the
health professionals. The storage details should you need them are as follows:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine after the expiry date
which is stated on the label and the carton after &#8220;EXP&#8221;. The expiry
date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in a refrigerator (2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:17">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>-<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine can also be stored in the original
carton outside of refrigerated storage up to a maximum of 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C for a single period of up
to six months, but not beyond the original expiry date. In this situation, do
not return to refrigerated storage again. Write the new expiry date on the
carton including day/month/year. Discard this medicine if not used by the new
expiry date or the expiry date printed on the carton, whichever is earlier.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is recommended that when Remicade is prepared
for infusion, it is used as soon as possible (within 3&nbsp;hours). However, if
the solution is prepared in germ&#8209;free conditions, it can be stored in a
refrigerator at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C to 8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C up to 28&nbsp;days and for
an additional 24&nbsp;hours at 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C after removal from the
refrigerator.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if it is discoloured or
if there are particles present.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Remicade contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is infliximab. Each vial
contains 100&nbsp;mg of infliximab. After preparation each ml contains 10&nbsp;mg
of infliximab</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are sucrose, polysorbate&nbsp;80,
monobasic sodium phosphate and dibasic sodium phosphate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Remicade looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is supplied as a glass vial
containing a powder for concentrate for solution for infusion. The powder is a
freeze&#8209;dried white pellet.</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade is produced in packs of 1, 2, 3, 4
or 5&nbsp;vials. Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Janssen Biologics B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB>Einsteinweg&nbsp;101</span></p>

<p class=MsoNormal><span lang=EN-GB>2333&nbsp;CB&nbsp;Leiden</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD Belgium BVBA/SPRL</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l/Tel: +32(0)27766211</span></p>
  <p class=MsoNormal><span lang=EN-GB>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>UAB Merck
  Sharp &amp; Dohme</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel. + 370 5
  278 02 47</span></p>
  <p class=MsoNormal><span lang=EN-GB>msd_lietuva@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#1052;&#1077;&#1088;&#1082;
  &#1064;&#1072;&#1088;&#1087; &#1080; &#1044;&#1086;&#1091;&#1084;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;.: +359 2 819 3737</span></p>
  <p class=MsoNormal><span lang=EN-GB>info&#8209;msdbg@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>MSD Belgium BVBA/SPRL</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l/Tel: +32(0)27766211</span></p>
  <p class=MsoNormal><span lang=EN-GB>dpoc_belux@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +420 233 010 111</span></p>
  <p class=MsoNormal><span lang=EN-GB>dpoc_czechslovak@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD Pharma Hungary Kft.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +36&nbsp;1&nbsp;888&nbsp;5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>hungary_msd@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=DE>MSD Danmark ApS</span></p>
  <p class=MsoNormal><span lang=DE>Tlf: + 45 4482 4000</span></p>
  <p class=MsoNormal><span lang=EN-GB>dkmail@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: 8007
  4433 (+356 99917558)</span></p>
  <p class=MsoNormal><span lang=EN-GB>malta_info@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>MSD SHARP &amp; DOHME GMBH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>
  <p class=MsoNormal><span lang=EN-GB>e&#8209;mail@msd.de</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: 0800 9999000</span></p>
  <p class=MsoNormal><span lang=EN-GB>(+31 23 5153153)</span></p>
  <p class=MsoNormal><span lang=EN-GB>medicalinfo.nl@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme O&Uuml;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel.:
  +372&nbsp;6144 200</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>msdeesti@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD (Norge) AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 32 20 73 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>msdnorge@msd.no</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD </span><span lang=EN-GB>&#913;.&#934;.&#914;.&#917;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;</span><span
  lang=EN-GB>: +30 210 98 97 300</span></p>
  <p class=MsoNormal><span lang=EN-GB>dpoc_greece@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 (0) 1 26 044</span></p>
  <p class=MsoNormal><span lang=DE>msd&#8209;medizin@merck.com</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Merck Sharp &amp; Dohme de Espa&ntilde;a,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 91 321 06 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>msd_info@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +48 22 549 51 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>msdpolska@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD France</span></p>
  <p class=MsoNormal><span lang=EN-GB>T&eacute;l: + 33 (0) 1 80 46 40 40</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Merck Sharp
  &amp; Dohme, Lda</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Tel: +351 21
  4465700</span></p>
  <p class=MsoNormal><span lang=EN-GB>inform_pt@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 385 1 6611 333</span></p>
  <p class=MsoNormal><span lang=EN-GB>croatia_info@merck.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT>Merck Sharp &amp; Dohme Romania S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +40 21 529 29 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>msdromania@merck.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme Ireland (Human Health)
  Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +353
  (0)1 2998700</span></p>
  <p class=MsoNormal><span lang=EN-GB>medinfo_ireland@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme, inovativna
  zdravila d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 1 5204 201</span></p>
  <p class=MsoNormal><span lang=EN-GB>msd.slovenia@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: + 354 535 7000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme, s. r. o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +421 2 58282010</span></p>
  <p class=MsoNormal><span lang=EN-GB>dpoc_czechslovak@merck.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>MSD Italia S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +39 06 361911</span></p>
  <p class=MsoNormal><span lang=EN-GB>medicalinformation.it@merck.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MSD Finland
  Oy</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Puh/Tel: +358
  (0)9 804 650</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>info@msd.fi</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Merck Sharp
  &amp; Dohme Cyprus Limited</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;.:
  800 00 673 (+357 22866700)</span></p>
  <p class=MsoNormal><span lang=EN-GB>cyprus_info@merck.com</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Merck Sharp
  &amp; Dohme (Sweden) AB</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +46 77
  5700488</span></p>
  <p class=MsoNormal><span lang=EN-GB>medicinskinfo@merck.com</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=304 valign=top style='width:227.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SIA Merck
  Sharp &amp; Dohme Latvija</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 371 67364224</span></p>
  <p class=MsoNormal><span lang=EN-GB>msd_lv@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=301 valign=top style='width:225.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Merck Sharp &amp; Dohme Limited</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 1992 467272</span></p>
  <p class=MsoNormal><span lang=EN-GB>medicalinformationuk@merck.com</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in
{MM/YYYY}.</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK4"><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
treated with Remicade should be given the patient reminder card.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for use and handling &#8211; storage conditions</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&#8209;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Remicade may be stored at temperatures up
to a maximum of 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:18">&nbsp;</del></span>&deg;C for a single period of up
to 6&nbsp;months, but not exceeding the original expiry date. The new expiry
date must be written on the carton. Upon removal from refrigerated storage,
Remicade must not be returned to refrigerated storage.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Instructions
for use and handling &#8211; reconstitution, dilution and administration</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In order to
improve the traceability of biological medicinal products, the tradename and
batch number of the administered medicinal product should be clearly recorded.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the dose and the
number of Remicade vials needed. Each Remicade vial contains 100&nbsp;mg
infliximab. Calculate the total volume of reconstituted Remicade solution
required.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Under aseptic conditions,
reconstitute each Remicade vial with 10&nbsp;ml of water for injections, using
a syringe equipped with a 21&#8209;gauge (0.8&nbsp;mm) or smaller needle.
Remove flip&#8209;top from the vial and wipe the top with a 70% alcohol swab.
Insert the syringe needle into the vial through the centre of the rubber
stopper and direct the stream of water for injections to the glass wall of the
vial. Gently swirl the solution by rotating the vial to dissolve the
lyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.
Foaming of the solution on reconstitution is not unusual. Allow the
reconstituted solution to stand for 5&nbsp;minutes. Check that the solution is
colourless to light yellow and opalescent. The solution may develop a few fine
translucent particles, as infliximab is a protein. Do not use if opaque
particles, discolouration, or other foreign particles are present.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dilute the total volume of
the reconstituted Remicade solution dose to 250&nbsp;ml with sodium chloride
9&nbsp;mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted
Remicade solution with any other diluent. The dilution can be accomplished by
withdrawing a volume of the sodium chloride 9&nbsp;mg/ml (0.9%) solution for
infusion from the 250&#8209;ml glass bottle or infusion bag equal to the volume
of reconstituted Remicade. Slowly add the total volume of reconstituted
Remicade solution to the 250&#8209;ml infusion bottle or bag. Gently mix. For
volumes greater than 250&nbsp;ml, either use a larger infusion bag (e.g. 500&nbsp;ml,
1000&nbsp;ml) or use multiple 250&nbsp;ml infusion bags to ensure that the
concentration of the infusion solution does not exceed 4&nbsp;mg/ml. If stored
refrigerated after reconstitution and dilution, the infusion solution must be
allowed to equilibrate at room temperature to 25<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&deg;C for 3&nbsp;hours prior to
Step&nbsp;4 (infusion). Storage beyond 24&nbsp;hours at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&#8209;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&deg;C applies to preparation of
Remicade in the infusion bag only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the infusion
solution over a period of not less than the infusion time recommended. Use only
an infusion set with an in&#8209;line, sterile, non&#8209;pyrogenic, low
protein&#8209;binding filter (pore size 1.2&nbsp;micrometre or less). Since no
preservative is present, it is recommended that the administration of the
solution for infusion is to be started as soon as possible and within
3&nbsp;hours of reconstitution and dilution. If not used immediately, in use
storage times and conditions prior to use are the responsibility of the user
and would normally not be longer than 24&nbsp;hours at 2<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&deg;C<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&#8209;<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>8<span class=msoDel><del
cite="mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]"
datetime="2020-08-20T15:19">&nbsp;</del></span>&deg;C, unless reconstitution/dilution
has been taken place in controlled and validated aseptic conditions. Do not
store any unused portion of the infusion solution for reuse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No physical biochemical
compatibility studies have been conducted to evaluate the co&#8209;administration
of Remicade with other agents. Do not infuse Remicade concomitantly in the same
intravenous line with other agents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect Remicade for
particulate matter or discolouration prior to administration. Do not use if
visibly opaque particles, discolouration or foreign particles are observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused product or waste
material should be disposed of in accordance with local requirements.</span></p>

</div>

</body>

</html>
